

Curriculum Vitae for Karen H. Lu, MD  
March 7, 2025  
Moffitt Cancer Center

Address: Executive Vice President, Physician-in-Chief  
President, Moffitt Medical Group  
12902 Magnolia Drive, Tampa, FL 33612  
Phone: (813)745-1099  
Email: [karen.lu@moffitt.org](mailto:karen.lu@moffitt.org)

**Education**

1986 MA, BA, Biochemical Sciences, cum laude  
Harvard University, Cambridge MA

**Postgraduate Training and Fellowship Appointments**

1991 MD, Yale University School of Medicine  
New Haven, CT

2021 MA, MHCM, Master of Healthcare Management  
Harvard Chan School of Public Health  
Boston, MA

1991 – 1995 Internship and Residency, Obstetrics and Gynecology  
Brigham and Women’s Hospital and Massachusetts General Hospital  
Harvard Medical School, Boston, MA

1996 – 1999 Fellowship, Gynecologic Oncology  
Brigham and Women’s Hospital, Harvard Medicine School  
Boston, MA

2000 – 2001 Certification, Coach Rice: Leadership Coaching  
Rice Jones Graduate School of Business  
Houston, TX

11/2007 – 4/2008 Clinical Safety and Effectiveness Training Program  
The University of Texas MD Anderson Cancer Center  
Houston, TX

9/2010 – 4/2011 Faculty Leadership Academy  
MD Anderson Cancer Center  
Houston, TX

9/2011 – 4/2012 Executive Leadership in Academic Medicine (ELAM)  
Drexel University College of Medicine  
Philadelphia, PA

5/2013 Management Training, Value Measurement Course  
Harvard Business School  
Boston, MA

**Academic Appointments**

1995 – 1996 Instructor  
Harvard Medical School, Boston, MA

1999 – 2004 Assistant Professor  
Department of Gynecologic Oncology and Reproductive Medicine  
Division of Surgery, The University of Texas MD Anderson Cancer  
Center, Houston, TX

9/2004 - 8/2008 Associate Professor, Department of Gynecologic Oncology  
The University of Texas M.D. Anderson Cancer Center, Houston, TX

9/2008 – 5/2024 Professor, Department of Gynecologic Oncology and Reproductive  
Medicine, Division of Surgery  
The University of Texas MD Anderson Cancer Center  
Houston, TX

**Administrative Appointments**

2000 – 5/2024 Co-Director, Multidisciplinary Gynecologic Cancer Translational  
Research Tumor Bank  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2001 – 2002 Chair, Multidisciplinary Endometrial Cancer Working Group  
Department of Gynecologic Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2001 – 2024 Director, Ovarian Cancer Screening Clinic  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2003 – 2006 Director, Research Fellows  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2004 – 2006 Chair, Multidisciplinary Endometrial Cancer Working Group  
Department of Gynecologic Oncology  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2005 – 2019 Director, Uterine Cancer Research Program  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2005 – 2024 Member, Graduate School of Biomedical Sciences  
The University of Texas Health Science Center  
Houston, TX

2006 – 2009 Chair, Program Steering Committee – Gynecologic Cancers  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2006 – 2024 Co-Director, Clinical Cancer Genetics  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2007 – 2012 Co – Director, Human Pedigree Analysis Resource  
Cancer Center Support Grant (CCSG)  
The University of Texas MD Anderson Cancer Center  
Houston, TX

11/2012 -5/2024 Department Chair, Department of Gynecologic Oncology and  
Reproductive Medicine, Division of Surgery  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2013 – 2024 Leader, Gynecologic Cancers Program  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2015 – 2024 Deputy Division Head for Research  
The University of Texas MD Anderson Cancer Center  
Houston, TX

6/2017 – 6/2018 Sr Vice President and Chief Clinical Officer, ad interim

Office of the Chief Clinical Officer  
The University of Texas MD Anderson Cancer Center  
Houston, TX  
9/2018 – 5/2024 Co-Director, Department of Gynecologic Oncology and Reproductive  
Medicine, Division of Surgery  
Blanton Davis Ovarian Cancer Center  
The University of Texas MD Anderson Cancer Center  
Houston, TX

**Other Appointments/Responsibilities**

1995 – 1996 Staff Physician, Vincent Memorial Obstetrics and Gynecology Service  
Massachusetts General Hospital  
Boston, MA  
2000 – 2006 Member, Cancer Prevention Committee  
Gynecologic Oncology Group  
Philadelphia, PA  
2002 – 2004 Advisory Board Member  
Texas Medical Center Women’s Health Network (WHN)  
Houston, TX  
2005 – 2006 Member, AACR Cancer Prevention Task Force  
Philadelphia, PA  
2005 – 2013 Member, NIH, PDQ Cancer Genetics Editorial Board  
Bethesda, MD  
2006 – 2024 Member, Education Resource Panel for Cancer Genetics  
Society of Gynecologic Oncologists  
Chicago, IL  
2007 – 2012 Member, Uterine Cancer Committee  
American Joint Committee (AJCC) on Cancer  
Chicago, IL  
2007 – 2012 Member, Committee on Practice Bulletins  
American College of Obstetrics and Gynecologist  
Washington, DC  
2007 – 2013 Member, National Cancer Institute (NCI)  
Gynecologic Cancer Scientific Steering Committee  
Uterine Corpus Task Force  
Bethesda, MD  
2009 – 2012 Member, Cancer Prevention Committee  
ASCO  
Washington, DC  
2011 - present Member, Advisory Board  
Epidemiology of Endometrial Cancer Consortium (E2C2)  
Boston, MA  
2013 – 2019 Member, NCI, Gynecologic Cancer Steering Committee  
Bethesda, MD  
2014 Chair, NIH/NCI GYN SPORE Monthly Teleconference  
Houston, TX  
2016 Member, NIH, PDQ Cancer Genetics Advisory Board  
Bethesda, MD  
2016 – 2017 Chair, Cancer Prevention Committee  
ASCO

2017 – 2019	Houston, TX Member External Advisory Committee of the Comprehensive Cancer Center University of Alabama at Birmingham Birmingham, AL
2019 – present	Member, Board of Directors Society of Gynecologic Oncology Chicago, IL
2021 – present	Member ASCO Research Committee (ARC) Alexandria, VA
2022	Chair, AACR Ovarian Cancer Research Grants Scientific Review Committee Houston, TX
1/2022 – present	Member, Break Through Cancer – Ovarian Cancer Team Boston, MA
1/2022 – present	Member, Tina’s Wish Scientific Advisory Board New York City, NY
2023 – present	President Elect II Society of Gynecologic Oncology Chicago, IL
2023 – present	Member, Cancer Center Support Grant Executive Committee Houston, TX

#### **Endowed Positions**

2009 – 2013	H.E.B. Professor of Cancer Research The University of Texas MD Anderson Cancer Center Houston, TX
8/2013 – 5/2024	J. Taylor Wharton Distinguished Chair in Gynecologic Oncology The University of Texas MD Anderson Cancer Center Houston, TX

#### **Licensure**

Texas	K8308, 1991 – 2024
Florida	ME168479, exp 1/31/2026

#### **Board Certifications**

1992 – 2022	Diplomate, National Board of Medical Examiners
12/2001 – 12/2023	Diplomate, American Board of Obstetrics and Gynecology, 950443
4/2003 – 12/2022	Diplomate, American Board of Obstetrics and Gynecology Division of Gynecologic Oncology

#### **Teaching Experience**

2002	Instructor, Cancer Genetic Counseling The University of Texas MD Anderson Cancer Center Houston, TX GSBS, Course Number: GS11 0012, Course hours: 1
2003	Instructor, Cancer Genetic Counseling The University of Texas MD Anderson Cancer Center Houston, TX GSBS, Course Number: GS11 0012, Course hours: 1
2004	Instructor, Cancer Genetic Counseling

The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS11 0012, Course hours: 1  
 2005 Instructor, Cancer Genetic Counseling  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS11 0012, Course hours: 1  
 2006 Instructor, Cancer Genetic Counseling  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS11 0012, Course hours: 1  
 2006 Instructor, Translational Research  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS21 0232, Course hours: 1  
 2007 Instructor, Cancer Genetic Counseling  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS11 0012, Course hours: 1  
 2007 Instructor, Translational Research  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS21 0232, Course hours: 1  
 2008 Instructor, Cancer Genetic Counseling  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS11 0012, Course Hours: 1  
 2008 Instructor, Translational Sciences: From Bench to Bedside and Back  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 Course Number: GS21 0232, Course Hours: 1  
 2009 Instructor, Cancer Genetic Counseling  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS11 0012, Course Hours: 1  
 2009 Instructor, Translational Sciences: From Bench to Bedside and Back  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GS21 0232, Course Hours: 1  
 4/2010 Instructor, Translational Sciences: From Bench to Bedside and Back  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GS21 0232, Course Hours: 1  
 2010 Instructor, Cancer Genetic Counseling  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS11 0012, Course Hours: 1  
 12/2011 Lecturer, 2011 Ovarian Cancer Survivors Course:  
 "Screening for Ovarian Cancer in the General Population:  
 A Clinician's Perspective"  
 The University of Texas MD Anderson Cancer Center and

12/2011 Foundation for Women's Cancer  
 Instructor, Cancer Genetic Counseling  
 The University of Texas MD Anderson Cancer Center  
 GSBS, Course Number: GS11 0012, Course Hours: 1

2011 Instructor, Translational Sciences: From Bench to Bedside and Back  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 Course Number: GS21 0232, Course Hours: 1

2/2012 Instructor, Cancer Genetic Counseling  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS11 0012, Course hours: 1

11/2012 Instructor, Translational Sciences: From Bedside to Bench and Back  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS11 0012, Course hours: 1

11/2013 Instructor, Translational Sciences: From Bedside to Bench and Back  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX  
 GSBS, Course Number: GS21 1232, Course hours: 1

2/2016 Instructor, Clinical and Translational Sciences: BRCAs, Course Hours: 1  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX

**Training program**

1999 Wound, Ostomy, Continence Nurse Education Program  
 The University of Texas MD Anderson Cancer Center  
 Houston, TX

**Other Formal Training**

2000 Lecturer, Tumor Markers and Ovarian Cancer Research  
 Cancer Information Service of the South-Central Region

2001 Lecturer, Endometrial Cancer Risk in women Taking Hormone Replacement  
 Therapy or Tamoxifen  
 The University of Texas MD Anderson Cancer Center Breast Medical Oncology  
 Seminar  
 Houston, TX

2001 Lecturer, Gestational Trophoblastic Disease  
 The University of Texas MD Anderson Cancer Center Medical Oncology Review  
 Course  
 Houston, TX

2001 Lecturer, Management of Women at Genetically High-Risk for Ovarian Cancer  
 The University of Texas MD Anderson Cancer Center Gynecologic Oncology  
 Multidisciplinary Conference  
 Houston, TX

2001 Lecturer, Screening for Endometrial and Ovarian Cancers in High-Risk Women  
 The University of Texas MD Anderson Cancer Center  
 Graduate Program for Cancer Genetics  
 Houston, TX

3/2002 Lecturer, Management of Women at Genetically High-Risk for Ovarian Cancer  
The University of Texas MD Anderson Cancer Center Gynecologic Oncology  
Multidisciplinary Conference  
Houston, TX

4/2002 Lecturer, Endometrial Working Group Update  
The University of Texas MD Anderson Cancer Center Gynecologic Oncology  
Multidisciplinary Conference  
Houston, TX

9/2002 Lecturer, Blanton-Davis Ovarian Cancer Research Program – Advisory Board  
Meeting, Research Update – High-Risk Studies  
The University of Texas MD Anderson Cancer Center  
Houston, TX

10/2002 Lecturer, Comprehensive Board Review in Hematology and Medical Oncology  
Uterine Cancer  
The University of Texas MD Anderson Cancer Center  
Houston, TX

10/2002 Lecturer, TWU  
The University of Texas MD Anderson and Women’s Health Network Event  
Early Detection Trials for Ovarian Cancer  
Houston, TX

10/2002 Lecturer, Update on Hereditary Gynecologic Cancers  
Gynecologic Oncology Multidisciplinary Conference Grand Rounds  
The University of Texas MD Anderson Cancer Center  
Houston, TX

3/2003 Lecturer, Management of Women at Genetically High-Risk for Ovarian Cancer  
The University of Texas MD Anderson Cancer Center Gynecologic Oncology  
Multidisciplinary Conference  
Houston, TX

5/2003 Forum Group Participant, Informal Conversations  
The University of Texas MD Anderson Cancer Center Fellows & Residents  
Houston, TX

10/2003 Lecturer, Comprehensive Board Review in Hematology and Medical Oncology  
Uterine Cancer  
The University of Texas MD Anderson Cancer Center  
Houston, TX

11/2003 Lecturer, Department of Gynecologic Oncology, Grand Rounds  
Hereditary Basis for Endometrial Cancer  
The University of Texas MD Anderson Cancer Center  
Houston, TX

3/2004 Lecturer, Management of Women at Genetically High-Risk for Ovarian Cancer  
The University of Texas MD Anderson Cancer Center Gynecologic Oncology  
Multidisciplinary Conference  
The University of Texas MD Anderson Cancer Center  
Houston, TX

10/2004 Lecturer, “Update on Hereditary Gynecologic Cancers”  
The University of Texas MD Anderson Cancer Center Gynecologic Oncology  
Multidisciplinary Conference  
The University of Texas MD Anderson Cancer Center  
Houston, TX

10/2004 Lecturer, A Comprehensive Board Review in Hematology and Medical Oncology  
Uterine Cancer

The University of Texas MD Anderson Cancer Center  
Houston, TX

10/2004 Lecturer, A Comprehensive Board Review in Hematology and Medical Oncology  
Uterine Cancer  
The University of Texas MD Anderson Cancer Center  
Houston, TX

12/2004 Lecturer, Department of Gynecologic Oncology  
Grand Rounds “Chemoprevention in Obese Women: An At-Risk Cohort”  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2/2005 Lecturer, Multidisciplinary Gynecologic Cancer Translational Research Tumor  
Bank  
The University of Texas MD Anderson Cancer Center  
Houston, TX

3/2005 Lecturer, Management of Women at Genetically High-Risk for Ovarian Cancer  
The University of Texas MD Anderson Cancer Center  
Houston, TX

10/2005 Lecturer, Early Detection of Women’s Cancers  
Partnering with the Women’s Health Community  
The University of Texas MD Anderson Cancer Center Gynecologic Oncology  
Multidisciplinary Conference  
Houston, TX

4/2006 Lecturer, Hereditary Gynecologic Cancer Syndrome:  
Clinical and Molecular Aspects, Seminars in Women’s Health  
Baylor College of Medicine  
Houston, TX

2/2007 Lecturer, Division of Surgery Grand Rounds:  
New Developments in Uterine Cancer Research  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2/2010 Chair and Lecturer, Institutional Grand Rounds:  
Hereditary Cancer Syndromes:  
Update on Prevention  
The University of Texas MD Anderson Cancer Center  
Houston, TX

### **Supervisory Teaching**

2003 Claudia Vidal, PhD Candidate

2003 Lei Deng, PhD Candidate

2004 Carol Linsner, Genetic Counseling master’s Candidate

2004 David Crotzer, MD, master’s Candidate

2004 Ran Xie, PhD Candidate

2005 Adrienne McCampbell, PhD Candidate

2008 Robin LaCour, The University of Texas MD Anderson Cancer Center MD, MPH  
Program

2009 Larissa Meyer, The University of Texas MD Anderson Cancer Center MD, MPH  
Program

2011 David Iglesias, The University of Texas MD Anderson Cancer Center MD, MPH  
Program

2019 Joseph Dottino, MD, master’s Candidate

2021 Han Cun, MD, master’s Candidate

**Examining Committees**

3/2021 Member, Examining Committee, Ana Bolivar, PhD

**Direct Supervision  
Medical Students**

Nancy Tran

**Graduate Students**

2010 Marissa Vineyard, Genetic Counseling master's Candidate  
2011 Suet Ying Kwan, PhD in Cancer Biology  
2006 Kaylene Whetstone, Genetic Counseling master's Candidate  
2008 Matthew L. Tschirgi, Genetic Counseling master's Candidate

**Postdoctoral Research Fellows**

2002 – 2003 Linda Chung, MD  
Gynecologic Oncology Post-Doctoral Training in Translational Research  
2007 – 2008 Janice Kwon, MD  
Gynecologic Oncology Post-Doctoral Training in Translational Research

**Clinical Residents and Fellows**

1999 – 2024 Clinical Supervision and Teaching 12 Felix Rutledge Residents  
The University of Texas MD Anderson Cancer Center  
Houston, TX  
1999 – 2024 Clinical Supervision and Teaching 4 Residents  
St Joseph Hospital  
Houston, TX  
1999 – 2024 Clinical Supervision and Teaching 5 Residents  
Lyndon B Johnson Hospital  
Houston, TX  
1999 – 2024 Clinical Supervision and Teaching 6 Residents  
Hermann Hospital  
Houston, TX  
1999 – 2024 Clinical Supervision and Teaching Clinical Fellows, 6 Fellows per year  
The University of Texas MD Anderson Cancer Center  
Houston, TX  
2000 Hyun Shvartsman, MD, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX  
2001 Jonathan Oh, MD, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX  
2002 – 2004 Brian Slomovitz, MD, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX  
2003 – 2005 Pam Soliman, MD, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center

2004 – 2006 Houston, TX  
Kathleen Schmeler, MD, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2005 – 2007 Mike Milam, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2006 – 2007 Shannon Westin, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2006 – 2008 Robin LaCour, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2007 – 2009 Larissa Meyer, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2008 – 2010 Jennifer Burzawa, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2009 – 2011 Marilyn Huang, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2010 – 2012 David Iglesias, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2011 – 2013 Laura Holman, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2012 – 2014 Kari Ring, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2013 – 2015 Michaela Onstad, Gynecologic Oncology Fellowship Program  
Basic Science Years  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2014 – 2016 Janelle Pakish, Gynecologic Oncology Fellowship Program  
Basic Science  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2015 – 2017 Shannon Armbruster, Gynecologic Oncology Fellowship Program  
Basic Science

2016 – 2018 The University of Texas MD Anderson Cancer Center  
Houston, TX  
Joseph Dottino, Gynecologic Oncology Fellowship Program  
Basic Science Years  
The University of Texas MD Anderson Cancer Center  
Houston, TX

### Teaching Outside Institution

10/2007 Lecturer, Disorders of Menstrual Cycle, Endometrium and Uterus, Part II  
Baylor College of Medicine  
Houston, TX

1/2013 Lecturer, “Introduction to Cancer Susceptibility Syndromes”  
University of Puerto Rico  
Puerto Rico

1/2013 Lecturer, BRCA 1 and 2: “Inherited Susceptibility to Breast and Ovarian Cancer”  
University of Puerto Rico  
Puerto Rico

9/2016 Lecturer, Causes of Cancer, Innovations in Cancer Treatment and Prevention:  
A Houston Story, Glasscock School of Continuing Studies at Rice University  
Houston, TX

### Honors and Awards

1986 Radcliffe Travelling Fellowship, Harvard, and Radcliffe Colleges

1986 Thomas Hoopes Prize "for outstanding undergraduate thesis,"  
Harvard University

1990 Farr Scholar, Yale Medical School

1990 Summer Research Fellowship, Yale Medical School

1994-1995 Administrative Chief Resident, Harvard Medical School

1995 APGO/CREOG Parke-Davis Scholars Award

1998-1999 Academic Training Award, American College of Obstetrics and Gynecology,  
ORTHO

1999-2002 Burroughs Wellcome Award, American Association of Obstetricians, and  
Gynecologists Foundation (AAOGF)

2001-2004 Liz Tilberis Scholar Award, Ovarian Cancer Research Fund

2003 Outstanding Educator Award  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2004 Mischell Award, Wyeth Annual Therapeutic Options for Menopausal Health  
Conference

2007 Faculty Educator of the Month (October)  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2007 Medical Honoree Award, Lynne Cohen Foundation

2009-2016 America's Top Doctors for Cancer, Castle Connally Medical LTD

2010 Faculty Achievement Award in Cancer Prevention  
The University of Texas MD Anderson Cancer Center  
Houston, TX

2010 The Margaret and James A. Elkins, Jr. Faculty Achievement Award in Cancer  
Prevention

2010 NIH Merit Award for PDQ Editorial Board

2011 Finalist, Julie and Ben Rogers Award for Excellence

	The University of Texas MD Anderson Cancer Center Houston, TX
2014-present	Member, The American Society for Clinical Investigation (ASCI)
2017-2018	Best Doctor in America, Best Doctors, Inc., Polling & Research
2017-2018	MD Anderson Cancer Center Press Ganey Top Performer The University of Texas MD Anderson Cancer Center Houston, TX
2017	The Claudia Cohen Research Foundation Prize Claudia Cohen Research Foundation
2018	American Cancer Society Award American Society of Clinical Oncology (ASCO)
2019	John Mendelsohn Award for Faculty Leadership The University of Texas MD Anderson Cancer Center Houston, TX
2019	Distinguished Mentor Award Nominee The University of Texas MD Anderson Cancer Center
2019-present	Elected Member, Association of American Physicians (AAP)
2019	Kathryn S. Stream Award The Greater Houston Women's Chamber of Commerce Houston, TX
2022	Victoria's Secret Global Fund for Women's Cancers Meritorious Awards, In Partnership with Pelotonia & American Association for Cancer Research (AACR)
2022-present	Pelotonia-AACR Women's Cancer Initiative Scientific Advisory Committee

## **Research Support**

### **Grants and Contracts**

#### **Funded**

Program Leader, 10%, Cancer Center Support (Core) Grant-Gynecological Cancer Program, 5 P30 CA016672-44, NIH/NCI, PI - Peter Pisters, 9/6/1998-present, \$92,010 (\$18,402/year)

Principal Investigator, 8%, Training of Academic Gynecologic Oncologists, 5 T32 CA101642-14, NIH/NCI, 7/1/2003-present, \$2,279,321 (\$447,524/year)

Co-Investigator, 2%, U.T. M.D. Anderson Cancer Center SPORE in Ovarian Cancer, 5 P50 CA217685-03, NIH/NCI, PI - Bast, Robert / Sood, Anil, 9/22/2017-8/31/2022 (\$98,375/year)

Co-Investigator, 5%, Targeting DRD2-Mediating signaling networks by novel imipridones in uterine serous cancer treatment, NIH/NCI, PI - Samuel Mok, 12/1/2020-11/30/2025, \$1,431,195 (\$286,239/year)

Co-Program Director, 0.12 months, IGNITE-TX (Increase Genetic Hereditary Cancer Testing in Texas), PP210034, Cancer Prevention & Research Institute of Texas, (CPRIT), PI - Jose Rauh-Hain, 8/31/2021-8/30/2024, \$949,961 (\$320,330/year)

Co-Investigator, 0.36 months, Targeting Ovarian Cancer Minimal Residual Disease (MRD) Using Immune and DNA Repair Directed Therapies, 00013847, Break Through Cancer, PI - Jazaeri, Amir, 3/1/2022-present, \$3,950,650

Principal Investigator-MDACC, 1.2 months, Understanding and intercepting ovarian carcinogenesis - the BTC Minimal Original Disease (MOD) Ovarian Cancer Team, 000013733, Break Through Cancer, 3/1/2022-present, \$1,410,152

Co-Investigator, MD Anderson Cancer Center EDNRN - Clinical Validation Center for Early Detection of Ovarian Cancer with a multiple marker algorithm, 2U01CA200462, NIH/NCI, PI - Bast, R., 6/2023

### **Completed**

Project Leader, 10%, Specialized Program of Research Excellence in Ovarian Cancer, 5P50CA83639, NIH/NCI, PI - Robert C. Bast, M.D., 9/30/1999-present, \$7,620,000 (\$1,536,098/year)

Principal Investigator, 5%, Endometrial Cancer Translational Research Program, UT M. D. Anderson Cancer Center Multidisciplinary Research Program (MRP), 5/1/2002-present, \$275,000 (\$91,667/year)

Principal Investigator, 2.88 months, MD Anderson Cancer Center Gynecologic SPORE for Uterine Cancers, 5 P50 CA098258-15, NIH/NCI, 9/1/2003-8/31/2021, \$7,540,000 (\$1,508,000/year)

Co-Principal Investigator, 1%, Lipotoxicity and Obesity Related Risk of Endometrial Carcinoma, CCTS 0006819(A), UTHSC-Houston, PI - Perry Bickel, MD, 9/1/2008-present, \$20,000

Co-Investigator, 1%, Rapamycin and IL-21 Conditioned CD8+T Cells for Adoptive Cellular Therapy, P50 CA159981-02, NIH/NCI, PI - Protul Shrikant and Cassian Yee, 9/18/2013-6/30/2019 (\$120,461/year)

Collaborator, 2%, Systemic Functional Characterization of RNA Editing in Endometrial Cancer, R01 CA175486-, NIH/NCI, PI - Han Liang, 4/22/2014-3/31/2019 (\$207,500/year)

Collaborator, 2%, Study of Biomarkers in Ovarian Cancer: Modulation by Activity & Diet Intervention, 5 R01 CA186700-05, NIH/NCI, PI - Cynthia Thomson / Karen Basen-Engquist, 1/1/2015-12/31/2019 (\$77,447/year)

Co-Investigator, 1%, Where it's at: The Effect of Adipose Tissue Location on Cancer Progression, ACS 126516, American Cancer Society (ACS), PI - Ann Klopp, 1/1/2015-12/31/2019 (\$151,913/year)

Co-Investigator, 10%, DNA Repair Therapies for Ovarian Cancer, SU2C-AACR-DT16-15, Dana-Farber Cancer Institute (via AACR Subaward), PI - Alan D'Andrea, 7/1/2015-6/30/2019 (\$341,305/year)

Collaborator, 5%, Early Detection of Ovarian Cancer with Tumor Associated Proteins and Autoantibodies, RP160145, Cancer Prevention & Research Institute of Texas (CPRIT), 3/1/2016-2/28/2021 (\$474,593/year)

Co-Investigator, 2%, MD Anderson Cancer Center EDNRN- CVC for Early Detection of Ovarian Cancer, 5 U01 CA200462-05, NIH/NCI, PI - Bast, Robert, 5/5/2016-3/31/2021, \$6,226,756 (\$624,640/year)

Co-Investigator, 1%, Molecular Mechanisms Underlying Environmental Effects that Influence Penetrance in Lynch Syndrome-Associated Endometrial Cancer, 5 R01 CA216103-04, NIH/NCI, PI - Melinda Yates, 4/5/2017-2/28/2022 (\$160,000/year)

Co-Investigator, 1%, Identification of ovarian cancer biomarkers in women at high-risk of developing ovarian cancer using emerging EFIRM Liquid Biopsy (eLB) technology, 2019-2020 Letter, The Honorable Tina Brozman Foundation, PI - Samuel Mok, 1/4/2019-12/31/2021, \$61,818 (\$30,909/year)

Collaborator, 2%, Magnified: Improving and Realizing the Cancer Prevention Impact of Genetic Knowledge, RP200260, Cancer Prevention & Research Institute of Texas (CPRIT), PI - You, 3/2/2020-2/28/2023, \$1,424,997 (\$474,999/year)

Co-Principal Investigator, 1%, Serum Glycoproteomic Signatures as Early Biomarkers for Ovarian Cancer, Venn Biosciences Corporation, PI - Robert Bast and Karen Lu, 7/15/2020-7/14/2022, \$96,000 (\$30,000/year)

Principal Investigator, 0.12 months, MD Anderson Cancer Center Gynecologic SPORE for Uterine Cancers Admin Supplement, 3 P50 CA098258-15S1, NIH/NCI, 9/1/2020-8/31/2021 (\$214,963/year)

## **Protocol**

### **Funded**

- 2001 - 2009 National Principal Investigator, Modulation of putative surrogate endpoint biomarkers in endometrial biopsies from women with HNPCC, GYN01-142
- 2001 - present National Co-Principal Investigator, Ovarian Cancer Screening Pilot Trial in High-Risk women, GYN01-142, 2001-present, Cancer Genetics Network (CGN)
- 2003 - present National Co-Principal Investigator, Prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer, GOG-0199, 2003-present, Gynecologic Oncology Group (GOG) 199
- 2003 - present National Principal Investigator, Use of the CA-125 Algorithm for the Early Detection of Ovarian Cancer in Low-Risk Women, ID01-022, 2003-present, Ovarian SPORE, Project I
- 2007 - 2009 Site Study Chairman, A Phase II, open-label, non-comparative, international, multicenter study to assess the efficacy and safety of KU-0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2- associated ovarian cancer, 2007-0098, KUDOS/WISP MAGENTA

## **Patents and Technology Licenses**

### **Patents**

Millennium Pharmaceuticals, Novel Compositions and Methods for the Identification, Assessment, Prevention and Therapy of Human Cancers, United States, MRI-027-1, 1/1/2001, Issued

Millennium Pharmaceuticals, Nucleic Acid Molecules and Proteins for the Identification, Assessment, Prevention, and Therapy of Ovarian Cancer, United States, MRI-10.097.340, Issued

## **Grant Reviewer/Service on Study Sections**

- 2007 ICER (Integrative and Clinical Endocrinology and Reproduction), NIH, ad hoc Reviewer
- 2011 SPORE, NCI, ad hoc Reviewer
- 2011 University of Virginia Cancer Center; P30/P50, NIH, Ad Hoc Member

## **INSTITUTIONAL COMMITTEE ACTIVITIES**

### **Moffitt Cancer Center**

- 2024 – present Chair, Moffitt Medical Group Board of Directors
- 2024 – present Chair, Moffitt Medical Group Executive Committee
- 2024 – present Member, Hospital Board of Directors
- 2024 – present Member, Joint Finance Committee
- 2024 – present Member, CEO Cabinet
- 2024 – present Member, Institute Board of Directors

2024 – present Member, Corporate Compliance Steering Committee  
2024 – present Member, Leadership Council  
2024 – present Member, Joint Strategy & Planning Committee  
2024 – present Member, Joint Enterprise, Risk, Audit & Compliance Committee

### **MD Anderson Cancer Center**

2001 – 2003 Member, Faculty Senate  
2002 – 2024 Member, Fellowship Admissions Committee  
2003 Member, Search Committee, Chair of Division of Anesthesiology and Critical Care  
2004 – 2010 Member, Blanton Davis Ovarian Cancer Research Program Executive Committee  
2004 – 2012 Member, Lab-Based Translational Research Committee, Dept of Gynecologic Oncology  
2005 – 2008 Member, Credentials Committee of the Medical Staff  
2006 Member, Search Committee, Division Head, Cancer Prevention and Population Sciences  
2008 – 2011 Member, Promotion and Tenure Committee  
2008 – 2012 Member, Faculty Health Committee  
2010 Member, Search Committee, Department Chair, Epidemiology  
2011 Member, Search Committee, Sr. Vice President, Academic Affairs  
2011 Member, Faculty Achievement Awards Committee  
2012 – 2013 Chair, Search Committee, Plastic Surgery  
2013 Member, Search Committee, Head of Division of Surgery  
2014 – 2015 Member, Search Committee, Pathology Chair  
2014 Member, Search Committee, Vice Provost Clinical & Interdisciplinary Research  
2015 – 2016 Clinical Department Chair, Roles and Responsibilities, E2-2 People Who Service  
2016 – 2017 Founder & Executive Chair, Community of Chairs  
2017 – 2018 Member, Professional Liability Committee  
2018 ex officio Voting Member, Kripke Legend Award Selection Committee  
2017 – 2018 Member, Executive Billing Compliant Committee  
2017 – 2018 Member, CCBA Executive Steering Committee  
2018 – 2019 Co-Chair, Search Committee, Radiation Oncology Division Head  
2018 – 2024 Chair, Quasi – Endowment for the Underserved  
2019 – 2021 Co-Chair, Nursing Chair Search Committee  
2021 – 2024 Member, SPMC Other Core Services Task Force  
2021 – 2024 Member, Institutional Awards Committee  
2021 – 2024 Member, Priority Review Committee

### **PUBLICATIONS**

#### **Peer-Reviewed Original Research Articles**

1. Williams DA, Hsieh K, DeSilva A, Mulligan RC. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. *J Exp Med* 166:210-8, 1987. PMID: 3298524.
2. Lu KH, Weitzel JN, Kodali S, Welch WR, Berkowitz RS, Mok SC. A novel 4-cM minimally deleted region on chromosome 11p15.1 associated with high grade nonmucinous epithelial ovarian carcinomas. *Cancer Res* 57(3):387-90, 2/1997. PMID: 9012461.
3. Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. *Cancer Res* 58(11):2328-30, 6/1998. PMID: 9622067.
4. Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. *Obstet Gynecol* 93(1):34-7, 1/1999. PMID: 9916952.

5. Garner EI, Chang-Lee WY, **Lu KH**, Goldstein DP, Berkowitz RS. Trophoblastic pulmonary embolization after hysterectomy for invasive complete mole. A case report *J Reprod Med* 44(10):908-12, 10/1999. PMID: 10554759.
6. Suzuki S, Moore DH, 2nd, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, **Lu K**, Mills G, Berchuck A, Gray JW. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. *Cancer Research* 60:5382-5, 2000.
7. Hoyte L, **Lu K**, Muto M, Nucci M, Versi E, Kikinis R, Fielding J. Magnetic resonance imaging based three-dimensional modeling of a complex vulvar tumor as a component of presurgical planning. *Journal of Women's Imaging*: 2:138-40, 2000.
8. **Lu KH**, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. *J Clin Oncol* 18:2728-32, 2000. PMID: 10894872.
9. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, **Lu K**, Schmandt R, Mills GB, Bast RC, Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. *Cancer Research* 61:5895-904, 2001.
10. Azevedo P, Verschraegen, CF, Kavanagh JJ, Kudelka AP, Freedman RS, **Lu K**, Deavers MT. Malignant mixed mesodermal tumor of the ovary treated with a cisplatin-irinotecan combination: case report. *European Journal of Gynaecological Oncology* 22:319-21, 2001.
11. Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, **Lu KH**, Silva EG. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. *Am J Surg Pathol* 26:1129-41, 2002. PMID: 12218569.
12. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, Modesitt SC, **Lu KH**, Geisler JP, Higgins RV, Magtibay PM, Cohn DE, Powell MA, Chu C, Stehman FB, van Nagell J. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. *Gynecol Oncol* 87:1-7, 2002. PMID: 12468335.
13. Crispens MA, Bodurka D, Deavers M, **Lu K**, Silva EG, Gershenson DM. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. *Obstetrics & Gynecology* 99:3-10, 2002.
14. Lee CM, Shvartsman H, Deavers MT, Wang SC, Xia W, Schmandt R, Bodurka DC, Atkinson EN, Malpica A, Gershenson DM, Hung MC, **Lu KH**. Beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. *Gynecol Oncol* 88:363-8, 2003. PMID: 12648588.
15. Slomovitz BM, Burke TW, Oh J, Broaddus RR, Eifel PJ, Atkinson EN, Silva EG, Gershenson DM, **Lu KH**. Clinical and pathologic characteristics of uterine papillary serous carcinoma (UPSC): A single institution review of 129 cases. *Gynecologic Oncology* 91:463-69, 2003.
16. Wu W, Slomovitz BM, Celestino J, Chung L, Thornton A, **Lu KH**. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. *Cancer Res* 63:6195-9, 2003. PMID: 14559803.
17. Schmandt RE, Broaddus R, **Lu KH**, Shvartsman H, Thornton A, Malpica A, Sun C, Bodurka DC, Gershenson DM. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. *Cancer* 98:758-64, 2003. PMID: 12910520.
18. Kim JH, Herlyn D, Wong KK, Park DC, Schorge JO, **Lu KH**, Skates SJ, Cramer DW, Berkowitz RS, Mok SC. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. *Clin Cancer Res* 9:4782-91, 2003. PMID: 14581349.

19. Jazaeri A, **Lu K**, Schmandt R, Harris C, Rao P, Chandramouli G, Gershenson D, Liu E. Molecular Determinants of Tumor Differentiation in Papillary Serous Ovarian Carcinoma. *Molecular Carcinogenesis* 36:53-59, 2003.
20. Shvartsman HS, **Lu KH**, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Jr, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. *Gynecol Oncol* 90:44-50, 2003. PMID: 12821340.
21. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JW, Berchuck A, **Lu K**, Smith D, Kimberly K, Hartmann L, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GR. Role of decreased levels of LLP-1 in accumulation of lysophosphatidic acid (LPA) in ovarian cancer. *Clinical Cancer Research* 9:3534-3545, 2003.
22. Chung L, Broaddus R, Crozier M, Luthra R, Levenback C, **Lu K**. Unexpected Endometrial Cancer at Prophylactic Hysterectomy in a Woman with HNPCC. *Obstetrics & Gynecology* 102:1152-1155, 2003.
23. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, **Lu KH**. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. *Gynecol Oncol* 91:463-9, 2003. PMID: 14675663.
24. Vidal CI, Mintz PJ, **Lu K**, Ellis LM, Manenti L, Giavazzi R, Gershenson D, Broaddus R, Liu J, Arap W, Pasqualini R. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. *Oncogene* 23:8859-67, 2004.
25. Slomovitz BM, **Lu KH**. Commenting on "HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? (88:263-5) by Santin AD". *Gynecol Oncol* 92:386-7; author reply 387, 2004. PMID: 14751194.
26. Bedrosian I, **Lu KH**, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. *Oncogene* 23:2648-57, 2004. PMID: 15007381.
27. Slomovitz BM, Sun CC, Ramirez PT, Bodurka DC, Diaz P, **Lu KH**. Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer? *Obstet Gynecol* 104:255-60, 2004. PMID: 15291996.
28. Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, **Lu KH**. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. *Gynecol Oncol* 95:32-6, 2004. PMID: 15385107.
29. Rosen DG, Wang L, Jain AN, **Lu KH**, Luo RZ, Yu Y, Liu J, Bast RC, Jr. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. *Clin Cancer Res* 10:6559-66, 2004. PMID: 15475444.
30. Malpica A, Deavers MT, **Lu K**, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. *Am J Surg Pathol* 28:496-504, 2004.
31. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, **Lu KH**. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. *J Clin Oncol* 22:3126-32, 2004. PMID: 15284264.
32. Oh JC, Wu W, Tortolero-Luna G, Broaddus R, Gershenson DM, Burke TW, Schmandt R, **Lu KH**. Increased plasma levels of insulin-like growth factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial cancer risk. *Cancer Epidemiol Biomarkers Prev* 13:748-52, 2004. PMID: 15159305.
33. **Lu KH**, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC, Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. *Clin Cancer Res* 10:3291-300, 2004. PMID: 15161682.

34. Soliman PT, Slomovitz BM, Broaddus RR, Sun CC, Oh JC, Eifel PJ, Gershenson DM, **Lu KH**. Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. *Gynecol Oncol* 94:456-62, 2004. PMID: 15297188.
35. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, **Lu KH**, Fishman D, Gray JW, Mills GB. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. *Nat Med* 10:1251-6, 2004. PMID: 15502842.
36. Broaddus RR, Lynch PM, **Lu KH**, Luthra R, Michelson SJ. Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome. *Mod Pathol* 17:981-9, 2004. PMID: 15143336.
37. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, **Lu KH**, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKC $\alpha$  contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. *Proc Natl Acad Sci U S A* 102:12519-24, 2005. PMID: 16116079.
38. Schmeler KM, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, **Lu KH**. Endometrial cancer in young, normal-weight women. *Gynecol Oncol* 99:388-92, 2005. PMID: 16051336.
39. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, **Lu KH**, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. *Cancer Res* 65:10602-12, 2005. PMID: 16288054.
40. Hartmann LC, **Lu KH**, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. *Clin Cancer Res* 11:2149-55, 2005. PMID: 15788660.
41. **Lu KH**, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, Bandipalliam P, Chen LM, Allen B, Conrad P, Terdiman J, Sun C, Daniels M, Burke T, Gershenson DM, Lynch H, Lynch P, Broaddus RR. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. *Obstet Gynecol* 105:569-74, 2005. PMID: 15738026.
42. Slomovitz BM, Ramondetta LM, Lee CM, Oh JC, Eifel PJ, Jhingran A, Burke TW, Gershenson DM, **Lu KH**. Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy. *Int J Gynecol Cancer* 15:510-6, 2005. PMID: 15882178.
43. Caudell JJ, Deavers MT, Slomovitz BM, **Lu KH**, Broaddus RR, Gershenson DM, Ramondetta LM. Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. *Appl Immunohistochem Mol Morphol* 13:167-70, 2005. PMID: 15894930.
44. Cheng YC, Saliba RM, Rondon G, Giralt SA, **Lu KH**, Bodurka DC, Gershenson DM, Champlin RE, Ueno NT. Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. *Haematologica* 90:1725-6, 2005. PMID: 16330461.
45. Liu Z, Wang LE, Wang L, **Lu KH**, Mills GB, Bondy ML, Wei Q. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. *Clin Cancer Res* 11:4968-76, 2005. PMID: 16000597.
46. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, Jr, **Lu KH**. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. *Clin Cancer Res* 11:6116-26, 2005. PMID: 16144910.
47. Rosen DG, Wang L, Atkinson JN, Yu Y, **Lu KH**, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC, Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. *Gynecol Oncol* 99:267-77, 2005. PMID: 16061277.

48. Lee CM, Slomovitz BM, Greer M, Sharma S, Gregurich MA, Burke T, **Lu KH**, Ramondetta LM. Practice patterns of SGO members for stage IIIA endometrial cancer. *Gynecol Oncol* 98:77-83, 2005. PMID: 15907988.
49. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, Burke TW, **Lu KH**. Risk factors for young premenopausal women with endometrial cancer. *Obstet Gynecol* 105:575-80, 2005. PMID: 15738027.
50. Soliman PT, Broaddus RR, Schmeler KM, Daniels MS, Gonzalez D, Slomovitz BM, Gershenson DM, **Lu KH**. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? *J Clin Oncol* 23:9344-50, 2005. PMID: 16361634.
51. Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM, Pearson HC, Berenson A, Ramirez PT, **Lu KH**, Bodurka DC. Are women ready for the HPV vaccine? *Gynecol Oncol* 103:151-4, 2006. PMID: 16551476.
52. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM, **Lu KH**. Association between adiponectin, insulin resistance, and endometrial cancer. *Cancer* 106:2376-81, 2006. PMID: 16639730.
53. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, **Lu K**, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study. *Cancer* 107:2745-51, 2006. PMID: 17109443.
54. Gershenson DM, Sun CC, **Lu KH**, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. *Obstet Gynecol* 108:361-8, 2006. PMID: 16880307.
55. Wu W, Slomovitz BM, Soliman PT, Schmeler KM, Celestino J, Milam MR, **Lu KH**. Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma. *Int J Gynecol Cancer* 16:1668-72, 2006. PMID: 16884382.
56. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, **Lu K**, Witkins SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. *Cancer Res* 66:1182-90, 2006.
57. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, **Lu KH**, Bast RC, Jr, Mills GB, Fang X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. *Cancer Res* 66:2740-8, 2006. PMID: 16510595.
58. Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, White KG, Luthra R, **Lu KH**. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. *Cancer* 106:87-94, 2006. PMID: 16323174.
59. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, **Lu KH**, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, Jr, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. *Clin Cancer Res* 12:3661-97, 2006. PMID: 16778094.
60. Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, **Lu KH**. Prophylactic Bilateral Salpingo-Oophorectomy Compared with Surveillance in Women with BRCA Mutations. *Obstet Gynecol* 108:515-520, 2006. PMID: 16946209.
61. Schmeler K, Lynch H, Chen L, Munsell M, Soliman P, Clark M, White K, Boyd-Rogers S, Conrad P, Yang K, Rubin M, Sun C, Slomovitz B, Gershenson D, **Lu K**. Prophylactic

- surgery for the reduction of gynecologic cancer risk in women with Lynch Syndrome (HNPCC). *N Eng J of Med* 354:261-9, 2006.
62. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, **Lu K**, Lynch P, Burke W, Press N. Recommendations for the care of individuals with an inherited predisposition to cancer: Hereditary nonpolyposis colorectal cancer (Lynch Syndrome). *JAMA* 296:1507-17, 2006.
  63. Schmandt RE, Bennett M, Clifford S, Thornton A, Jiang F, Broaddus RR, Sun CC, **Lu KH**, Sood AK, Gershenson DM. The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. *Cancer Biol Ther* 5:1136-41, 2006. PMID: 16855388.
  64. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, **Lu K**, Lokshin A. Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. *Gynecol Oncol* 107:58-65, 7/2007. PMID: PMCOMC2777971.
  65. Vogel KJ, Atchley DP, Erlichman J, Broglio KR, Ready KJ, Valero V, Amos CI, Hortobagyi GN, **Lu KH**, Arun B. BRCA1 and BRCA2 genetics testing in hispanic patients: mutation prevalence and evaluation of the BRCAPro risk assessment model. *J Clin Oncol* 25(29):4635-41, 2007.
  66. Shvartsman HS, Sun CC, Bodurka DC, Majajan V, Crispens M, **Lu KH**, Deavers MT, Malpica A, Silva EG, Gershenson DM. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. *Gynecol Oncol* 105:625-9, 2007.
  67. Bedrosian I, Lee C, Tucker SL, Palla SL, **Lu K**, Keyomarsi K. Cyclin E associated kinase activity predicts response to platinum-based chemotherapy. *Clin Cancer Res* 13:4800-6, 2007.
  68. **Lu KH**, Kauff ND. Does a BRCA mutation plus tamoxifen equal hysterectomy? *Gynecol Oncol* 104(1):3-4, 2007. PMID: 17222708.
  69. Saldivar JS, **Lu KH**, Liang D, Gu J, Hunang M, Vlastos AT, Follen M, Wu X. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. *Gynecol Oncol* 107: S223-9, 2007.
  70. **Lu K**, Schorge JO, Rodabaugh KJ, Daniels MS, Sun CC, Soliman PT, White KG, Luthra R, Gershenson DM, Broaddus RR. Prospective determination of prevalence of Lynch Syndrome in young women with endometrial cancer. *J Clin Oncol* 25:58-64, 2007.
  71. Milam MR, Celestino J, Wu W, Broaddus RR, Slomovitz BM, Schmeler KM, Soliman PT, Gershenson DM, Wang H, Ellenson LH, **Lu KH**. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the PTEN heterozygote murine model. *Am J Obstet Gynecol* 196:247.e1-247.e5, 2007.
  72. Wong KK, **Lu KH**. Significantly higher expression of ER, PR and ECAD in advanced-stage low-grade ovarian serous carcinomas as revealed by immunohistochemical analysis. *Intl J of Gynecol Pathol* 26(4):404-9, 2007.
  73. Lancaster JM, Bethan Powell C, Kauff ND, Cass I, Chen LM, **Lu KH**, Mutch DG, Berchuck A, Karlan BY, Herzog TJ: Society of Gynecologic Oncologists Education Committee. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. *Gynecol Oncol* 107:159-62, 2007.
  74. Milam MR, Gu J, Yang H, Celestino J, Wu W, Horwitz IB, Lacour RA, Westin SN, Gershenson DM, Wu X, **Lu K**. STK15 F3II Polymorphism is associated with increased uterine cancer risk: A pilot study. *Gynecol Oncol* 107:71-4, 2007.
  75. Milam MR, Sood AK, King S, Bassett RL, **Lu KH**, Slomovitz BM, Coleman RL. Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. *Obstet & Gynecol* 109:641-6, 2007.

76. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, **Lu KH**, Bast RC Jr. Urinary mesothelin provides greater sensitivity for early-stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. *Gynecol Oncol* 106:490-7, 2007.
77. Milam MR, Soliman PT, Chung LH, Schmeler KM, Bassett RL, Broaddus RR, **Lu KH**. Loss of phosphatase and tensin homologue deleted on chromosome 10 and phosphorylation of mammalian target of rapamycin are associated with progesterone refractory endometrial hyperplasia. *Int J Gynecol Cancer* 18(1):146-51, Jan-Feb, 1/2008. e-Pub 4/2007. PMID: 17466036.
78. Klopp AH, Jhingran A, Ramdas L, Story MD, Broadus RR, **Lu KH**, Eifel PJ, Buchholz TA. Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome. *Int J Radiat Oncol Biol Phys* 71(1):226-36, 5/2008. PMID: 18406887.
79. **Lu KH**, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. *Clin Cancer Res* 14(9):2543-50, 5/2008. PMID: 18451215.
80. Kwon JS, **Lu KH**. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women. *Obstet Gynecol* 112(1):56-63, 7/2008. PMID: 18591308.
81. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, **Lu KH**. Cost-effectiveness analysis of prevention strategies for gynecologic cancers in Lynch Syndrome. *Cancer* 113(2):326-35, 7/2008. PMID: 18506736.
82. Soliman PT, Bassett RL, Wilson EB, Boyd-Rogers S, Schmeler KM, Milam MR, Gershenson DM, **Lu KH**. Limited public knowledge of obesity and endometrial cancer risk: what women know. *Obstet Gynecol* 112(4):835-42, 10/2008. PMID: 18827126.
83. Lacour RA, Daniels MS, Westin SN, Meyer LA, Burke CC, Burns KA, Kurian S, Webb NF, Pustilnik TB, **Lu KH**. What women with ovarian cancer think and know about genetic testing. *Gynecol Oncol* 111(1):132-6, 10/2008. e-Pub 8/2008. PMID: 18684498.
84. Westin SN, Lacour RA, Urbauer DL, Luthra R, Bodurka D, **Lu KH**, Broaddus R. Carcinoma of the lower uterine segment: A newly described association with Lynch syndrome. *J Clin Oncol* 26(36):5965-71, 2008. e-Pub 11/2008. PMID: PMC2645115.
85. Batista LI, **Lu KH**, Beahm EK, Arun BK, Bodurka DC, Meric-Bernstam F. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. *BMC Cancer* 8:101, 2008. PMID: PMC2362122.
86. Feng W, Marquez RT, **Lu Z**, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC Jr. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently downregulated in human ovarian cancers by loss of heterozygosity and promoter methylation. *Cancer* 112(7):1489-502, 2008.
87. Zhai J, Rosen DG, **Lu K**, Liu J. Loss of DNA mismatch repair gene hMLH6 in ovarian cancer is histotype specific. *Int J Clin & Exp Pathol* 1(6):502-9, 2008.
88. Wu W, Celestino J, Milam MR, Schmeler KM, Broaddus RR, Ellenson LH, **Lu KH**. Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. *Int J Gynecol Cancer* 18(2):529-38, 2008.
89. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC JR, **Lu K**. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. *Gynecol Oncol* 110(2):196-201, 2008.
90. Ready KJ, Vogel KJ, Atchley DP, Broglio KR, Solomon KK, Amos C, **Lu KH**, Hortobagyi GN, Arun B. Accuracy of the BRCAPRO model among women with bilateral breast cancer. *Cancer* 115(4):725-30, 2/2009. PMID: 19127556.

91. Zhang Q, Shen Q, Celestino J, Milam MR, Westin SN, Lacour RA, Meyer LA, Shipley GL, Davies PJ, Deng L, McCampbell AS, Broaddus RR, **Lu KH**. Enhanced estrogen-induced proliferation in obese rat endometrium. *Am J Obstet Gynecol* 200(2):186.e1-8, 2/2009. PMID: 19185100.
92. Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, **Lu KH**, Hortobagyi GN, Arun BK. Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. *Cancer* 115(8):1598-604, 4/2009. PMID: PMC2680417.
93. Gershenson DM, Sun CC, Bodurka D, Coleman RL, **Lu KH**, Sood AK, Deavers M, Malpica AL, Kavanagh JJ. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. *Gynecol Oncol* 114(1):48-52, 7/2009. e-Pub 4/2009. PMID: 19361839.
94. Schmeler KM, Daniels MS, Brandt AC, **Lu KH**. Endometrial cancer in an adolescent: a possible manifestation of Cowden Syndrome. *Obstet Gynecol* 114(2 Pt 2):1-7, 8/2009. PMID: 19622968.
95. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, **Lu KH**, Gershenson DM, Wong KK. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. *Mod Pathol* 22(9):1243-50, 9/2009. e-Pub 6/2009. PMID: PMC2736318.
96. Daniels MS, Urbauer DL, Stanley JL, Johnson KG, **Lu KH**. Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer. *Genet Med* 11(9):624-8, 9/2009. e-Pub 7/2009. PMID: 19606053.
97. Klopp AH, Jhingran A, Ramondetta L, **Lu K**, Gershenson DM, Eifel PJ. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation. *Gynecol Oncol* 115(1):6-11, 10/2009. e-Pub 7/2009. PMID: 19632709.
98. Westin SN, Broaddus RR, Deng L, McCampbell A, **Lu KH**, Lacour RA, Milam MR, Urbauer DL, Mueller P, Pickar JH, Loose DS. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression. *Cancer Biol Ther* 8(22):2126-35, 11/2009. e-Pub 11/2009. PMID: PMC2872176.
99. Basen-Engquist K, Scruggs S, Jhingran A, Bodurka DC, **Lu K**, Ramondetta L, Hughes D, Carmack Taylor C. Physical activity, and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. *Am J Obstet Gynecol* 200(3):288, 2009.
100. Kwon JS, Daniels MS, Sun CC, **Lu KH**. Preventing Future Cancers by Testing Women with Ovarian Cancer for BRCA Mutations. *J Clin Oncol* 28(4):675-82, 2/2010. e-Pub 10/2009. PMID: 19841329.
101. Schmeler KM, Daniels MS, Soliman PT, Broaddus RR, Deavers MT, Vu TM, Chang GJ, **Lu KH**. Primary Peritoneal Cancer After Bilateral Salpingo-Oophorectomy in Two Patients with Lynch Syndrome. *Obstet Gynecol* 115(2):432-4, 2/2010. PMID: PMC4250042.
102. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, **Lu K**, Badgwell D, Bast RC, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. *J Clin Oncol* 28(13):2159-66, 5/2010. e-Pub 4/2010. PMID: PMC2860434.
103. Meyer LA, Anderson ME, Lacour RA, Suri A, Daniels MS, Urbauer DL, Noguerras-Gonzalez GM, Schmeler KM, Gershenson DM, **Lu KH**. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. *Obstet Gynecol* 115(5):945-52, 5/2010. PMID: 20410767.
104. Moroney J, Wheler J, Hong D, Naing A, Falchook G, Bodurka D, Coleman R, **Lu K**, Xiao L, Kurzrock R. Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. *Gynecol Oncol* 117(3):467-72, 6/2010. e-Pub 3/2010. PMID: PMC2882061.

105. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, **Lu K**, Schmutzler RK, Matulonis U, Wickens M, Tutt A. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet* 376(9737):245-51, 7/2010. e-Pub 7/2010. PMID: 20609468.
106. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, **Lu KH**, Mills GB. Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit from Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer. *J Clin Oncol* 28(22):3570-6, 8/2010. e-Pub 7/2010. PMID: PMC2917312.
107. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, **Lu KH**, Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. *J Clin Oncol* 28(27):4214-20, 9/2010. e-Pub 8/2010. PMID: 20733129.
108. Brandt AC, Tschirgi ML, Ready KJ, Sun C, Darilek S, Hecht J, Arun BK, **Lu KH**. Knowledge, attitudes, and clinical experience of physicians regarding preimplantation genetic diagnosis for hereditary cancer predisposition syndromes. *Fam Cancer* 9(3):479-87, 9/2010. e-Pub 4/2010. PMID: 20431955.
109. Ready KJ, Daniels MS, Sun CC, Peterson SK, Northrup H, **Lu KH**. Obstetrics/Gynecology Residents' Knowledge of Hereditary Breast and Ovarian Cancer and Lynch Syndrome. *J Cancer Educ* 25(3):401-4, 9/2010. e-Pub 2/2010. PMID: 20186516.
110. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemenev LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, Dörk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, **Lu K**, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC, Wellcome Trust Case-Control Consortium, Beesley J, Webb PM, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group, Ovarian Cancer Association Consortium (OCAC), Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, Dürst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD, Ovarian Cancer Association Consortium (OCAC). A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nat Genet* 42(10):874-9, 10/2010. e-Pub 9/2010. PMID: PMC3020231.
111. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK, **Lu KH**, Gershenson DM. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. *Am J Pathol* 177(4):1611-7, 10/2010. e-Pub 8/2010. PMID: PMC2947258.
112. Nabili NH, Broaddus RR, McCampbell AS, **Lu KH**, Lynch HT, Chen LM, Loose DS. Sex hormone regulation of survivin gene expression. *J Endocrinol* 207(2):237-243, 11/2010. e-Pub 8/2010. PMID: PMC4270120.
113. Slomovitz BM, **Lu KH**, Johnston T, Coleman RL, Munsell M, Broaddus RR, Walker C, Ramondetta LM, Burke TW, Gershenson DM, Wolf J. A phase 2 study of the oral

- mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. *Cancer* 116(23):5415-9, 12/2010. e-Pub 8/2010. PMID: 20681032.
114. Liang D, Meyer L, Chang DW, Lin J, Pu X, Ye Y, Gu J, Wu X, **Lu K**. Genetic Variants in MicroRNA Biosynthesis Pathways and Binding Sites Modify Ovarian Cancer Risk, Survival, and Treatment Response. *Cancer Res* 70(23):9765-76, 12/2010. e-Pub 11/2010. PMID: 21118967.
  115. Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, **Lu KH**, Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors. *J Clin Oncol* 28(27):4214-4220, 2010. PMID: 20733129.
  116. Zhang X, Zhang Q, Zhang J, Qiu L, Yan SS, Feng J, Sun Y, Huang X, **Lu KH**, Li Z. FATS is a transcriptional target of p53 and associated with antitumor activity. *Mol Cancer* 9:244, 2010. e-Pub 9/2010. PMCID: PMC2946289.
  117. An J, Wei Q, Liu Z, **Lu KH**, Cheng X, Mills GB, Wang LE. Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. *Int J Mol Epidemiol Genet* 1(1):1-10, 2010. PMCID: PMC2916180.
  118. Huang M, Sun C, Boyd-Rogers S, Burzawa J, Milbourne A, Keeler E, Yzquierdo R, Lynch P, Peterson SK, **Lu K**. Prospective study of combined colon and endometrial cancer screening in women with lynch syndrome: a patient-centered approach. *J Oncol Pract* 7(1):43-7, 1/2011. PMCID: PMC3014510.
  119. Soliman PT, Cui X, Zhang Q, Hankinson SE, **Lu KH**. Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. *Am J Obstet Gynecol* 204(2): 167.e1-5, 2/2011. e-Pub 11/2010. PMCID: PMC3032826.
  120. Vineyard MA, Daniels MS, Urbauer DL, Deavers MT, Sun CC, Boerwinkle E, Bodurka DC, Gershenson DM, Crawford J, **Lu KH**. Is low-grade serous ovarian cancer part of the tumor spectrum of Hereditary Breast and Ovarian Cancer? *Gynecol Oncol* 120(2):229-32, 2/2011. e-Pub 12/2010. PMID: 21126756.
  121. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, **Lu KH**, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD, PLCO Project Team. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. *Cancer Prev Res (Phila)* 4(3):375-83, 3/2011. PMCID: PMC3057372.
  122. Ready K, Gutierrez-Barrera AM, Amos C, Meric-Bernstam F, **Lu K**, Hortobagyi G, Arun B. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. *Breast J* 17(2):210-2, 3/2011. e-Pub 2/2011. PMID: 21294809.
  123. Yates MS, Meyer LA, Deavers MT, Daniels MS, Keeler ER, Mok SC, Gershenson DM, **Lu KH**. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis. *Cancer Prev Res (Phila)* 4(3):463-70, 3/2011. e-Pub 1/2011. PMCID: PMC3048908.
  124. Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, **Lu KH**, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. *Cancer Prev Res (Phila)* 4(3):365-74, 3/2011. PMCID: PMC3085251.
  125. Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, Ramondetta LM, Tortolero-Luna G, Urbauer DL, Chang S, Gershenson DM, Brown J, **Lu KH**. Prospective evaluation of insulin resistance among endometrial cancer patients. *Am J Obstet Gynecol* 204(4): 355.e1-7, 4/2011. e-Pub 2/2011. PMCID: PMC4286377.
  126. Lacour RA, Westin SN, Meyer LA, Wingo SN, Schorge JO, Brooks R, Mutch D, Molina A, Sutphen R, Barnes M, Elder J, Teoh D, Powell CB, Choubey V, Blank S, Macdonald HR, Brady MF, Urbauer DL, Bodurka D, Gershenson DM, **Lu KH**. Improved survival in non-

- Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. *Gynecol Oncol* 121(2):358-63, 5/2011. e-Pub 1/2011. PMID: PMC3310886.
127. Westin SN, Sun CC, **Lu KH**, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC. Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. *Cancer* 117(12):2659-67, 6/2011. e-Pub 12/2010. PMID: PMC4254830.
  128. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, **Lu KH**. Testing Women with Endometrial Cancer to Detect Lynch Syndrome. *J Clin Oncol* 29(16):2247-52, 6/2011. e-Pub 5/2011. PMID: 21537049.
  129. King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, **Lu KH**, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated with Differentiation and Survival in Ovarian Cancer. *Am J Surg Pathol* 35(6):904-12, 6/2011. e-Pub 3/2011. PMID: PMC3095702.
  130. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, **Lu Y**, Stemke-Hale K, Dyer MD, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB. High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability. *Cancer Discov* 1(2):170-185, 7/2011. e-Pub 6/2011. PMID: PMC3187555.
  131. Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, **Lu K**. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. *Cancer Prev Res* 4(9):1401-8, 9/2011. PMID: 21893500.
  132. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, **Lu KH**, Bast RC. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early-stage epithelial ovarian cancer. *Gynecol Oncol* 122(3):548-53, 9/2011. e-Pub 6/2011. PMID: PMC3152646.
  133. Ready K, Arun BK, Schmeler KM, Uyei A, Litton JK, **Lu KH**, Sun CC, Peterson SK. Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. *Fam Cancer* 10(4):673-9, 12/2011. e-Pub 6/2011. PMID: 21681553.
  134. Yin J, **Lu K**, Lin J, Wu L, Hildebrandt MA, Chang DW, Meyer L, Wu X, Liang D. Genetic Variants in TGF- $\beta$  Pathway Are Associated with Ovarian Cancer Risk. *PLoS One* 6(9): e25559, 2011. e-Pub 9/2011. PMID: PMC3184159.
  135. Han CH, Huang YJ, **Lu KH**, Liu Z, Mills GB, Wei Q, Wang LE. Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. *J Exp Clin Cancer Res* 30(1):5, 2011. e-Pub 1/2011. PMID: PMC3025876.
  136. Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, **Lu K**, Hortobagyi GN, Arun BK. Earlier age of onset of BRCA mutation-related cancers in subsequent generations. *Cancer* 118(2):321-5, 1/2012. e-Pub 9/2011. PMID: 21913181.
  137. Moore LE, Pfeiffer RM, Zhang Z, **Lu KH**, Fung ET, Bast RC. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. *Cancer* 118(1):91-100, 1/2012. e-Pub 6/2011. PMID: PMC3385508.
  138. Klopp AH, Zhang Y, Solley T, Amaya-Manzanares F, Marini F, Andreeff M, Debeb B, Woodward W, Schmandt R, Broaddus R, **Lu K**, Kolonin MG. Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. *Clin Cancer Res* 18(3):771-82, 2/2012. e-Pub 12/2011. PMID: 22167410.

139. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, **Lu KH**, Kurzrock R. PI3K/AKT/mTOR Inhibitors in Patients with Breast and Gynecologic Malignancies Harboring PIK3CA Mutations. *J Clin Oncol* 30(8):777-82, 3/2012. e-Pub 1/2012. PMID: PMC3295566.
140. Wang LE, Ma H, Hale KS, Yin M, Meyer LA, Liu H, Li J, **Lu KH**, Hennessy BT, Li X, Spitz MR, Wei Q, Mills GB. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. *J Cancer Res Clin Oncol* 138(3):377-85, 3/2012. e-Pub 12/2011. PMID: PMC3526101.
141. Moore RG, Miller MC, Steinhoff MM, Skates SJ, **Lu KH**, Lambert-Messerlian G, Bast RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. *Am J Obstet Gynecol* 206(4): 351.e1-8, 4/2012. e-Pub 12/2011. PMID: PMC3985608.
142. Moore RG, Miller MC, Eklund EE, **Lu KH**, Bast RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. *Am J Obstet Gynecol* 206(4): 349.e1-7, 4/2012. e-Pub 12/2011. PMID: PMC3987114.
143. Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, Furmaga WB, Redding SW, **Lu KH**, Bast RC, McDevitt JT. Programmable Bio-Nano-Chip Systems for Serum CA125 Quantification: Towards Ovarian Cancer Diagnostics at the Point-of-Care. *Cancer Prev Res (Phila)* 5(5):706-16, 5/2012. e-Pub 4/2012. PMID: PMC3677577.
144. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, **Lu KH**, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: A Gynecologic Oncology Group Study. *Cancer* 118(12):3087-94, 6/2012. e-Pub 11/2011. PMID: 22072418.
145. Pande M, Wei C, Chen J, Amos CI, Lynch PM, **Lu KH**, Lucio LA, Boyd-Rogers SG, Bannon SA, Mork ME, Frazier ML. Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital-based Lynch syndrome registry. *Fam Cancer* 11(3):441-7, 9/2012. e-Pub 6/2012. PMID: PMC3475767.
146. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, **Lu KH**, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. *Br J Cancer* 107(10):1776-82, 11/2012. e-Pub 10/2012. PMID: PMC3493866.
147. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, **Lu KH**, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. *Genome Res* 22(11):2120-9, 11/2012. e-Pub 10/2012. PMID: PMC3483541.
148. Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, **Lu KH**, Hortobagyi GN, Arun BK. Genotype in BRCA-associated Breast Cancers. *Breast J* 19(1):87-91, Jan - Feb, 1/2013. e-Pub 12/2012. PMID: 23231005.
149. Shirvani SM, Klopp AH, Likhacheva A, Jhingran A, Soliman PT, **Lu KH**, Eifel PJ. Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer. *Pract Radiat Oncol* 3(1): e21-8, Jan - Mar, 1/2013. e-Pub 5/2012. PMID: 24674269.
150. Jhingran A, Ramondetta LM, Bodurka DC, Slomovitz BM, Brown J, Levy LB, Garcia ME, Eifel PJ, **Lu KH**, Burke TW. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIa (1988) uterine papillary serous carcinoma of the endometrium. *Gynecol Oncol* 129(2):304-9, 5/2013. e-Pub 2/2013. PMID: 23385150.

151. Zhang Q, Celestino J, Schmandt R, McCampbell AS, Urbauer DL, Meyer LA, Burzawa JK, Huang M, Yates MS, Iglesias D, Broaddus RR, **Lu KH**. Chemopreventive effects of metformin on obesity-associated endometrial proliferation. *Am J Obstet Gynecol* 209(1):24.e1-24.e12, 7/2013. e-Pub 3/2013. PMID: PMC3819145.
152. Huang M, Djordejevic B, Yates MS, Urbauer D, Sun C, Burzawa J, Daniels M, Westin SN, Broaddus R, **Lu K**. Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome. *Cancer* 119(16):3027-33, 8/2013.
153. **Lu KH**, Loose DS, Yates MS, Nogueras-Gonzalez GM, Munsell MF, Chen LM, Lynch H, Cornelison T, Boyd-Rogers S, Rubin M, Daniels MS, Conrad P, Milbourne A, Gershenson DM, Broaddus RR. Prospective Multicenter Randomized Intermediate Biomarker Study of Oral Contraceptive versus Depo-Provera for Prevention of Endometrial Cancer in Women with Lynch Syndrome. *Cancer Prev Res (Phila)* 6(8):774-81, 8/2013. e-Pub 5/2013. PMID: PMC3737517.
154. **Lu KH**, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. *Cancer* 119(19):3454-61, 10/2013. e-Pub 8/2013. PMID: PMC3982191.
155. Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, **Lu KH**, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G, GCIG Endometrial Cancer Clinical Trials Planning Meeting. Gynecologic Cancer InterGroup (GCIG) endometrial cancer clinical trials planning meeting: taking endometrial cancer trials into the translational era. *Int J Gynecol Cancer* 23(8):1528-34, 10/2013. PMID: 24257568.
156. Iglesias DA, Yates MS, van der Hoeven D, Rodkey TL, Zhang Q, Co NN, Burzawa J, Chigurupati S, Celestino J, Bowser J, Broaddus R, Hancock JF, Schmandt R, **Lu KH**. Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy. *Mol Cancer Ther* 12(12):2847-56, 12/2013. e-Pub 9/2013. PMID: PMC3883498.
157. Daniels MS, Urbauer DL, Zangeneh A, Batte BA, Dempsey KM, **Lu KH**. Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist. *Gynecol Oncol* 131(3):619-23, 12/2013. e-Pub 10/2013. PMID: PMC4123330.
158. Shen H, Fridley BL, Song H, Lawrenson K, Cunningham JM, Ramus SJ, Cicek MS, Tyrer J, Stram D, Larson MC, Köbel M, PRACTICAL Consortium, Ziogas A, Zheng W, Yang HP, Wu AH, Wozniak EL, Woo YL, Winterhoff B, Wik E, Whittemore AS, Wentzensen N, Weber RP, Vitonis AF, Vincent D, Vierkant RA, Vergote I, Van Den Berg D, Van Altena AM, Tworoger SS, Thompson PJ, Tessier DC, Terry KL, Teo SH, Templeman C, Stram DO, Southey MC, Sieh W, Siddiqui N, Shvetsov YB, Shu XO, Shridhar V, Wang-Gohrke S, Severi G, Schwaab I, Salvesen HB, Rzepecka IK, Runnebaum IB, Rossing MA, Rodriguez-Rodriguez L, Risch HA, Renner SP, Poole EM, Pike MC, Phelan CM, Pelttari LM, Pejovic T, Paul J, Orlow I, Omar SZ, Olson SH, Odunsi K, Nickels S, Nevanlinna H, Ness RB, Narod SA, Nakanishi T, Moysich KB, Monteiro AN, Moes-Sosnowska J, Modugno F, Menon U, McLaughlin JR, McGuire V, Matsuo K, Adenan NA, Massuger LF, Lurie G, Lundvall L, Lubinski J, Lissowska J, Levine DA, Leminen A, Lee AW, Le ND, Lambrechts S, Lambrechts D, Kupryjanczyk J, Krakstad C, Konecny GE, Kjaer SK, Kiemeny LA, Kelemen LE, Keeney GL, Karlan BY, Karevan R, Kalli KR, Kajiyama H, Ji BT, Jensen A, Jakubowska A, Iversen E, Hosono S, Høgdall CK, Høgdall E, Hoatlin M, Hillemanns P, Heitz F, Hein R, Harter P, Halle MK, Hall P, Gronwald J, Gore M, Goodman MT, Giles GG, Gentry-Maharaj A, Garcia-Closas M, Flanagan JM, Fasching PA, Ekici AB, Edwards R, Eccles D, Easton DF, Dürst M, du Bois A, Dörk T, Doherty JA, Despierre E, Dansonka-Mieszkowska A, Cybulski C, Cramer DW, Cook LS, Chen X, Charbonneau B, Chang-Claude J, Campbell I, Butzow R, Bunker CH, Brueggmann D, Brown R, Brooks-Wilson A,

- Brinton LA, Bogdanova N, Block MS, Benjamin E, Beesley J, Beckmann MW, Bandera EV, Baglietto L, Bacot F, Armasu SM, Antonenkova N, Anton-Culver H, Aben KK, Liang D, Wu X, **Lu K**, Hildebrandt MA, Australian Ovarian Cancer Study Group, Australian Cancer Study, Schildkraut JM, Sellers TA, Huntsman D, Berchuck A, Chenevix-Trench G, Gayther SA, Pharoah PD, Laird PW, G. Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nat Commun* 4:1628, 2013. PMID: PMC3848248.
159. Wang Y, Ye Y, Lin J, Meyer L, Wu X, **Lu K** and Liang D. Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome. *Mol Carcinog*:doi: 10.1002/mc.22111, 2013.
160. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilknikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, kConFab Investigators, Radice P, Schmutzler RK, SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M, Ontario Cancer Genetics Network, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Toland AE, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT, HEBON, EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ, GEMO Study Collaborators, Zlowocka-Perlowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschm. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genet* 9(3):e1003212, 2013. e-Pub 3/2013. PMID: PMC3609646.
161. Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, Woodward WA, **Lu K**, Salimian B, Nagrath D, Klopp AH. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. *PLoS One* 8(12): e81859, 2013. e-Pub 12/2013. PMID: PMC3847080.
162. Permut-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Australian Cancer Study, Australian Ovarian Cancer Study, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, Consortium of Investigators of Modifiers of BRCA1/2, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher

- DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeny LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, **Lu KH**, Lubinski J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nat Commun* 4:1627, 2013. PMID: PMC3709460.
163. Meng QH, Xu E, Hildebrandt MA, Liang D, **Lu K**, Ye Y, Wagar EA, Wu X. Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome. *Clin Chem* 60(1):222-32, 1/2014. e-Pub 10/2013. PMID: 24146310.
164. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, Rider DN, Sellers TA, Tworoger SS, Poole E, Risch HA, Salvesen HB, Kiemeny LA, Baglietto L, Giles GG, Severi G, Trabert B, Wentzensen N, Chenevix-Trench G, for AOCs/ACS group, Whittemore AS, Sieh W, Chang-Claude J, Bandera EV, Orlow I, Terry K, Goodman MT, Thompson PJ, Cook LS, Rossing MA, Ness RB, Narod SA, Kupryjanczyk J, **Lu K**, Butzow R, Dörk T, Pejovic T, Campbell I, Le ND, Bunker CH, Bogdanova N, Runnebaum IB, Eccles D, Paul J, Wu AH, Gayther SA, Hogdall E, Heitz F, Kaye SB, Karlan BY, Anton-Culver H, Gronwald J, Hogdall CK, Lambrechts D, Fasching PA, Menon U, Schildkraut J, Pearce CL, Levine DA, Kjaer SK, Cramer D, Flanagan JM, Phelan CM, Brown R, Massuger LF, Song H, Doherty JA, Krakstad C, Liang D, Odunsi K, Berchuck A, Jensen A, Lubinski J, Nevanlinna H, Bean YT, Lurie G, Ziogas A, Walsh C, Despierre E, Brinton L, Hein A, Rudolph A, Dansonka-Mieszkowska A, Olson SH, Harter P, Tyrer J, Vitonis AF, Brooks-Wilson A, Aben KK, Pike MC, Ramus SJ, Wik E, Cybulski C, Lin J, Sucheston L, Edwards R, McGuire V, Lester J, du Bois A, Lundvall L, Wang-Gohrke S, Szafron LM, Lambrechts S, Yang H, Beckmann MW, Pelttari LM, Van Altena AM, van den Berg D, Halle MK, Gentry-Maharaj A, Schwaab I, Chandran U, Menkiszak J, Ekici AB, Wilkens LR, Leminen A, Modugno F, Friel G, Rothstein JH, Vergote I, Garcia-Closas M, Hildebrandt MA, Sobiczewski P, Kelemen LE, Pharoah PD, Moysich K, Knutson KL, Cunningham JM, Fridley BL, Goode EL. Risk of ovarian cancer and the NF- $\kappa$ B pathway: genetic association with IL1A and TNFSF10. *Cancer Res* 74(3):852-61, 2/2014. e-Pub 11/2013. PMID: PMC3946482.
165. **Lu KH**, Wood ME, Daniels M, Burke C, Ford J, Kauff ND, Kohlmann W, Lindor NM, Mulvey TM, Robinson L, Rubinstein WS, Stoffel EM, Snyder C, Syngal S, Merrill JK, Wollins DS, Hughes KS, American Society of Clinical Oncology. American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers. *J Clin Oncol* 32(8):833-40, 3/2014. e-Pub 2/2014. PMID: PMC3940540.
166. Wood ME, Kadluek P, Pham TH, Wollins DS, **Lu KH**, Weitzel JN, Neuss MN, Hughes KS. Quality of Cancer Family History and Referral for Genetic Counseling and Testing Among Oncology Practices: A Pilot Test of Quality Measures as Part of the American

- Society of Clinical Oncology Quality Oncology Practice Initiative. *J Clin Oncol* 32(8):824-9, 3/2014. e-Pub 2/2014. PMID: 24493722.
167. Holman LL, **Lu KH**, Bast RC, Hernandez MA, Bodurka DC, Skates S, Sun CC. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. *Am J Obstet Gynecol* 210(3): 257.e1-6, 3/2014. e-Pub 11/2013. PMCID: PMC4001707.
  168. Piha-Paul SA, Wheler JJ, Fu S, Levenback C, **Lu K**, Falchook GS, Naing A, Hong DS, Tsimberidou AM, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. *Oncotarget* 5(7):1846-55, 4/2014. PMCID: PMC4039109.
  169. Zhang Q, Schmandt R, Celestino J, McCampbell A, Yates MS, Urbauer DL, Broaddus RR, Loose DS, Shipley GL, **Lu KH**. CGRRF1 as a novel biomarker of tissue response to metformin in the context of obesity. *Gynecol Oncol* 133(1):83-9, 4/2014. PMCID: PMC4077340.
  170. Basen-Engquist K, Carmack C, Brown J, Jhingran A, Baum G, Song J, Scruggs S, Swartz MC, Cox MG, **Lu KH**. Response to an exercise intervention after endometrial cancer: Differences between obese and non-obese survivors. *Gynecol Oncol* 133(1):48-55, 4/2014. PMCID: PMC3979927.
  171. Daniels MS, Babb SA, King RH, Urbauer DL, Batte BA, Brandt AC, Amos CI, Buchanan AH, Mutch DG, **Lu KH**. Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women with High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study. *J Clin Oncol* 32(12):1249-55, 4/2014. e-Pub 3/2014. PMID: 24638001.
  172. Nebgen DR, Hartman CL, Rhodes H, Munsell M, Woodard TL, **Lu KH**. Abnormal uterine bleeding as the presenting symptom of hematopoietic cancer. *Obstet Gynecol* 123 Suppl 1:30S, 5/2014. PMID: 24770162.
  173. Holman LL, Friedman S, Daniels MS, Sun CC, **Lu KH**. Acceptability of Prophylactic Salpingectomy with Delayed Oophorectomy as Risk-Reducing Surgery Among BRCA Mutation Carriers. *Gynecol Oncol* 133(2):283-6, 5/2014. e-Pub 2/2014. PMCID: PMC4035022.
  174. Earp MA, Kelemen LE, Magliocco AM, Swenerton KD, Chenevix-Trench G, Australian Cancer Study, Australian Ovarian Cancer Study Group, Lu Y, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Despierre E, Vergote I, Lambrechts S, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Friel G, Moysich KB, Odunsi K, Sucheston-Campbell L, Lurie G, Goodman MT, Carney ME, Thompson PJ, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Nevanlinna H, Pelttari LM, Butzow R, Bunker CH, Modugno F, Edwards RP, Ness RB, du Bois A, Heitz F, Schwaab I, Harter P, Karlan BY, Walsh C, Lester J, Jensen A, Kjær SK, Høgdall CK, Høgdall E, Lundvall L, Sellers TA, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Giles GG, Baglietto L, Severi G, Southey MC, Liang D, Wu X, **Lu K**, Hildebrandt MA, Levine DA, Bisogna M, Schildkraut JM, Iversen ES, Weber RP, Berchuck A, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Chandran U, Orlow I, Olson SH, Wik E, Salvesen HB, Borge L, Halle MK, van Altena AM, Aben KK, Kiemeny LA, Massuger LF, Pejovic T, Bean YT, Cybulski C, Gronwald J, Lubinski J, Wentzensen N, Brinton LA, Lissowska J, Garcia-Closas M, Dicks E, Dennis J, Easton DF, Song H, Tyrer JP, Pharoah PD, Eccles D, Campbell IG, Whittemore AS, McGuire V, Sieh W, Rothstein JH, Flanagan JM, Paul J, Brown R, Phelan CM, Risch HA, McLaughlin JR, Narod SA, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Gayther SA, Ramus SJ, Wu AH, Pearce CL, Pike MC, Dansonka-Mieszkowska A, Rzepecka IK, Szafron LM, Kupryjanczyk J, Cook LS, Le ND, Brooks-Wilson A, Ovarian Cancer Association Consortium. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. *Hum Genet* 133(5):481-97, 5/2014. e-Pub 11/2013. PMCID: PMC4063682.

175. Hou MM, Liu X, Wheler J, Naing A, Hong D, Bodurka D, Schmeler K, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Hu CY, **Lu K**, Kurzrock R, Fu S. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. *Anticancer Res* 34(5):2349-55, 5/2014. PMID: 24778042.
176. Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, Fleming G, Gaffney D, Greven K, **Lu K**, Miller D, Moore D, Petereit D, Schefter T, Small W, Yashar C, Viswanathan AN. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. *Pract Radiat Oncol* 4(3):137-44, May - Jun, 5/2014. e-Pub 3/2014. PMID: 24766678.
177. Meyer LA, Slomovitz BM, Djordjevic B, Westin SN, Iglesias DA, Munsell MF, Jiang Y, Schmandt R, Broaddus RR, Coleman RL, Galbincea JM, **Lu KH**. The Search Continues: Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer. *Int J Gynecol Cancer* 24(4):713-7, 5/2014. e-Pub 3/2014. PMID: PMC4039301.
178. Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs EG, Perrier ND, **Lu KH**, Arun BK, Woodard TL, Schover LR, Litton JK. Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. *Fam Cancer* 13(2):291-9, 6/2014. e-Pub 9/2013. PMID: PMC4159051.
179. Bruegl AS, Djordjevic B, Batte B, Daniels M, Fellman B, Urbauer D, Luthra R, Sun C, **Lu KH**, Broaddus RR. Evaluation of clinical criteria for the identification of Lynch syndrome among unselected patients with endometrial cancer. *Cancer Prev Res (Phila)* 7(7):686-97, 7/2014. e-Pub 4/2014. PMID: PMC4090057.
180. Batte BA, Bruegl AS, Daniels MS, Ring KL, Dempsey KM, Djordjevic B, Luthra R, Fellman BM, **Lu KH**, Broaddus RR. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for lynch syndrome. *Gynecol Oncol* 134(2):319-25, 8/2014. e-Pub 6/2014. PMID: PMC4125501.
181. Burton-Chase AM, Hovick SR, Sun CC, Boyd-Rogers S, Lynch PM, **Lu KH**, Peterson SK. Gynecologic cancer screening and communication with health care providers in women with Lynch syndrome. *Clin Genet* 86(2):185-9, 8/2014. e-Pub 8/2013. PMID: PMC3909028.
182. Liu Y, Patel L, Mills GB, **Lu KH**, Sood AK, Ding L, Kucherlapati R, Mardis ER, Levine DA, Shmulevich I, Broaddus RR, Zhang W. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. *J Natl Cancer Inst* 106(9), 9/2014. e-Pub 9/2014. PMID: PMC4200060.
183. Nebgen DR, **Lu KH**, Rimes S, Keeler E, Broaddus R, Munsell MF, Lynch PM. Combined colonoscopy and endometrial biopsy cancer screening results in women with Lynch syndrome. *Gynecol Oncol* 135(1):85-9, 10/2014. e-Pub 8/2014. PMID: 25149916.
184. Sherman ME, Piedmonte M, Mai PL, Ioffe OB, Ronnett BM, Van Le L, Ivanov I, Bell MC, Blank SV, DiSilvestro P, Hamilton CA, Tewari KS, Wakeley K, Kauff ND, Yamada SD, Rodriguez G, Skates SJ, Alberts DS, Walker JL, Minasian L, **Lu K**, Greene MH. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. *J Clin Oncol* 32(29):3275-83, 10/2014. e-Pub 9/2014. PMID: PMC4178524.
185. Co NN, Iglesias D, Celestino J, Kwan SY, Mok SC, Schmandt R, **Lu KH**. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53. *Cancer* 120(22):3457-68, 11/2014. e-Pub 7/2014. PMID: PMC4221493.
186. Bannon SA, Mork M, Vilar E, Peterson SK, **Lu K**, Lynch PM, Rodriguez-Bigas MA, You YN. Patient-reported disease knowledge and educational needs in Lynch syndrome: findings of an interactive multidisciplinary patient conference. *Hered Cancer Clin Pract* 12(1):1, 2014. e-Pub 2/2014. PMID: PMC3922108.

187. Bruegl AS, Djordjevic B, Urbauer DL, Westin SN, Soliman PT, **Lu KH**, Luthra R, Broaddus RR. Utility of MLH1 Methylation Analysis in the Clinical Evaluation of Lynch Syndrome in Women with Endometrial Cancer. *Curr Pharm Des* 20(11):1655-63, 2014. e-Pub 7/2013. PMID: PMC3895501.
188. Shadfan BH, Simmons AR, Simmons GW, Ho A, Wong J, **Lu KH**, Bast RC, McDevitt JT. A Multiplexable, Microfluidic Platform for the Rapid Quantitation of a Biomarker Panel for Early Ovarian Cancer Detection at the Point-of-Care. *Cancer Prev Res (Phila)* 8(1):37-48, 1/2015. e-Pub 11/2014. PMID: PMC4465398.
189. Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, **Lu KH**, Roach N, Limburg PJ, American Society of Clinical Oncology, European Society of Clinical Oncology. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology clinical practice guideline endorsement of the familial risk-colorectal cancer: European society for medical oncology clinical practice guidelines. *J Clin Oncol* 33(2):209-17, 1/2015. e-Pub 12/2014. PMID: 25452455.
190. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Gerdes AM, Ejlersen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S, EMBRACE, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM, GEMO Study Collaborators, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leener K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomäki K, Nevanlinna H, Collée JM, Rookus MA, Oosterwijk JC, Breast Cancer Family Registry, Tihomirova L, Tung N, Hamann U, Isacs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB, HEBON, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR, KConFab Investigators, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmal M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J, Australian Cancer Study (Ovarian Cancer Investigators), Australian Ovarian Cancer Study Group, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet* 47(2):164-71, 2/2015. e-Pub 1/2015. PMID: PMC4445140.
191. Meyer LA, Nick AM, Shi Q, Wang XS, Williams L, Brock T, Iniesta MD, Rangel K, **Lu KH**, Ramirez PT. Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients. *Gynecol Oncol* 136(3):440-5, 3/2015. e-Pub 1/2015. PMID: 25647455.
192. Slomovitz BM, Jiang Y, Yates MS, Soliman PT, Johnston T, Nowakowski M, Levenback C, Zhang Q, Ring K, Munsell MF, Gershenson DM, **Lu KH**, Coleman RL. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. *J Clin Oncol* 33(8):930-6, 3/2015. e-Pub 1/2015. PMID: PMC4348638.
193. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, CIMBA Consortium, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H,

- Stenmark-Askmal M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlersen B, Gerdes AM, Hansen Tv, Ramón y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, De Paepe A, Poppe B, Claes K, De Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomäki K, van der Hout AH, Hog. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA* 313(13):1347-61, 4/2015. PMID: PMC4537700.
194. Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, **Lu KH**, Valero V, Arun BK. Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. *Breast J* 21(3):260-7, May-Jun, 5/2015. e-Pub 3/2015. PMID: 25789811.
195. Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, **Lu KH**. Salpingectomy as a Means to Reduce Ovarian Cancer Risk. *Cancer Prev Res (Phila)* 8(5):342-348, 5/2015. e-Pub 1/2015. PMID: PMC4417454.
196. Dempsey KM, Broaddus R, You YN, Noblin SJ, Mork M, Fellman B, Urbauer D, Daniels M, **Lu K**. Is it all Lynch syndrome? An assessment of family history in individuals with mismatch repair-deficient tumors. *Genet Med* 17(6):476-84, 6/2015. e-Pub 10/2014. PMID: 25341111.
197. Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, **Lu KH**, Sood AK, Coleman RL, Ramirez PT. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. *Gynecol Oncol* 137(3):553-558, 6/2015. e-Pub 3/2015. PMID: 25827290.
198. Lu Y, Cuellar-Partida G, Painter JN, Nyholt DR, Australian Ovarian Cancer Study, International Endogene Consortium (IEC), Morris AP, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Wicklund KG, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Peltari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, Lu KH, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeny LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Gilks CB, Gronwald J, Jakubowska A, Lubinski J, Gawelko J, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D,

- Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Risch HA, Goode EL, Schildkraut JM, Webb PM, Pearce CL, Berchuck A, Pharoah PD, Montgomery GW, Zondervan KT, Chenevix-Trench G, McGregor S. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. *Hum Mol Genet.* e-Pub 7/2015. PMID: 26231222.
199. Gershenson DM, Bodurka DC, **Lu KH**, Nathan LC, Milojevic L, Wong KK, Malpica A, Sun CC. Impact of Age and Primary Disease Site on Outcome in Women with Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. *J Clin Oncol* 33(24):2675-82, 8/2015. e-Pub 7/2015. PMCID: PMC4534528.
200. Jiang Y, Malouf GG, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Spano JP, Broaddus R, Tannir NM, Khayat D, **Lu KH**, Su X. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. *Oncotarget.* e-Pub 9/2015. PMID: 26431491.
201. Ho JC, Allen PK, Jhingran A, Westin SN, **Lu KH**, Eifel PJ, Klopp AH. Management of nodal recurrences of endometrial cancer with IMRT. *Gynecol Oncol* 139(1):40-6, 10/2015. e-Pub 7/2015. PMID: 26193429.
202. Rauh-Hain JA, Diver E, Meyer LA, Clemmer J, **Lu KH**, Del Carmen MG, Schorge JO. Patterns of care, associations, and outcomes of chemotherapy for uterine serous carcinoma: Analysis of the National Cancer Database. *Gynecol Oncol* 139(1):77-83, 10/2015. e-Pub 8/2015. PMID: 26325526.
203. Westin SN, Ju Z, Broaddus RR, Krakstad C, Li J, Pal N, **Lu KH**, Coleman RL, Hennessy BT, Klemperer SJ, Werner HM, Salvesen HB, Cantley LC, Mills GB, Myers AP. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. *Mol Oncol* 9(8):1694-703, 10/2015. e-Pub 5/2015. PMCID: PMC4584169.
204. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, **Lu KH**, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. *Nat Rev Cancer* 15(11):668-79, 10/2015. PMID: 26493647.
205. Patrono MG, Iniesta MD, Malpica A, **Lu KH**, Fernandez RO, Salvo G, Ramirez PT. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review. *Gynecol Oncol* 139(3):568-72, 12/2015. e-Pub 9/2015. PMID: 26407480.
206. Rauh-Hain JA, Pepin KJ, Meyer LA, Clemmer JT, **Lu KH**, Rice LW, Uppal S, Schorge JO, Del Carmen MG. Management for Elderly Women with Advanced-Stage, High-Grade Endometrial Cancer. *Obstet Gynecol* 126(6):1198-206, 12/2015. e-Pub 11/2015. PMID: 26551187.
207. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, Win AK, Senter L, Lipkin SM, Stadler ZK, Macrae FA, Lynch HT, Weitzel JN, de la Chapelle A, Syngal S, Lynch P, Parry S, Jenkins MA, Gallinger S, Holter S, Aronson M, Newcomb PA, Burnett T, Le Marchand L, Pichurin P, Hampel H, Terdiman JP, **Lu KH**, Thibodeau S, Lindor NM. PMS2 monoallelic mutation carriers: the known unknown. *Genet Med* 18(1):13-9, 1/2016. e-Pub 4/2015. PMCID: PMC4834863.
208. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, EMBRACE, McGuffog L, Ellis S, Feng B, Buys SS, Hopper JL, Southey MC, Tesoriero A, kConFab Investigators, James PA, Bruinsma F, Campbell IG, Australia Ovarian Cancer

- Study Group, Broeks A, Schmidt MK, Hogervorst FB, HEBON, Beckman MW, Fasching PA, Fletcher O, Johnson N, Sawyer EJ, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Hamann U, Marne F, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry KL, Poole EM, Tworoger SS, Dorfling CM, van Rensburg EJ, Godwin AK, Guénel P, Truong T, GEMO Study Collaborators, Stoppa-Lyonnet D, Damiola F, Mazoyer S, Sinilnikova OM, Isaacs C, Maugard C, Bojesen SE, Flyger H, Gerdes AM, Hansen TV, Jensen A, Kjaer SK, Hogdall C, Hogdall E, Pedersen IS, Thomassen M, Benitez J, González-Neira A, Osorio A, Hoya Mde L, Segura PP, Diez O, Lazaro C, Brunet J, Anton-Culver H, Eunjung L, John EM, Neuhausen SL, Ding YC, Castillo D, Weitzel JN, Ganz PA, Nussbaum RL, Chan SB, Karlan BY, Lester J, Wu A, Gayther S, Ramus SJ, Sieh W, Whittermore AS, Monteiro AN, Phelan CM, Terry MB, Piedmonte M, Offit K, Robson M, Levine D, Moysich KB, Cannioto R, Olson SH, Daly MB, Nathanson KL, Domchek SM, **Lu KH**, Liang D, Hildebrandt MA, Ness R, Modugno F, Pearce L, Goodman MT, Thompson PJ, Brenner H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Brüning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari LM, Aittomäki K, Butzow R, Bogdanova NV, Dörk T, Lindblom A, Margolin S, Rantala J, Kosma VM, Mannermaa A, Lambrechts D, Neven P, Claes KB, Maerken TV, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira MR, Collavoli A, Hallberg E, Olson JE, Goode EL, Hart SN, Shimelis H, Cunningham JM, Giles GG, Milne RL, Healey S, Tucker K, Haiman CA, Henderson BE, Goldberg MS, Tischkowitz M, Simard J, Soucy P, Eccles DM, Le N, Borresen-Dale AL, BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *J Natl Cancer Inst* 108(2), 2/2016. e-Pub 11/2015. PMID: PMC4907358.
209. Westin SN, Sun CC, Tung CS, Lacour RA, Meyer LA, Urbauer DL, Frumovitz MM, **Lu KH**, Bodurka DC. Survivors of gynecologic malignancies: impact of treatment on health and well-being. *J Cancer Surviv* 10(2):261-70, 4/2016. e-Pub 8/2015. PMID: PMC4744585.
210. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A, Australian Ovarian Cancer Study Group, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H, Breast Cancer Family Register, Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brüning T, Budzylowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KB, Collée JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks EM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Silva Idos S, du Bois A, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards RP, Ehrencrona H, Ejlersen B, Ekici AB, Ellis SD, EMBRACE, Engel C, Eriksson M, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Fontaine A, Fortuzzi S, Fostira F, Fridley BL, Friebel T, Friedman E, Friel G, Frost D, Garber J, García-Closas M, Gayther SA, GEMO Study Collaborators, GENICA Network, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goodman MT, Gore M, Greene MH, Grip M, Gronwald J, Gschwantler Kaulich D, Guénel P, Guzman SR, Haeberle L, Haiman CA, Hall P, Halverson SL, Hamann U, Hansen TV, Harter P, Hartikainen JM, Healey S, HEBON, Hein A, Heitz F, Henderson BE, Herzog J, T Hildebrandt MA, Høgdall CK, Høgdall E, Hogervorst FB, Hopper JL, Humphreys K, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska K, Jensen A,

- Jens. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecol Oncol* 141(2):386-401, 5/2016. e-Pub 5/2015. PMID: PMC4630206.
211. Gockley AA, Rauh-Hain JA, Anders AM, Meyer LA, Clemmer J, **Lu KH**, Clark RM, Schorge JO, Del Carmen MG. Patterns of Care, Predictors, and Outcomes of Adjuvant Therapy for Early- and Advanced-Stage Uterine Clear Cell Carcinoma: A Population-Based Analysis. *Int J Gynecol Cancer* 26(4):697-704, 5/2016. e-Pub 1/2016. PMID: 26825834.
  212. Khawaja MR, Nick AM, Madhusudanannair V, Fu S, Hong D, McQuinn LM, Ng CS, Piha-Paul SA, Janku F, Subbiah V, Tsimberidou A, Karp D, Meric-Bernstam F, **Lu KH**, Naing A. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. *Cancer Chemother Pharmacol* 77(5):973-7, 5/2016. e-Pub 3/2016. PMID: 27014780.
  213. Di Guilmi J, Salvo G, Mehran R, Sood AK, Coleman RL, **Lu KH**, Vaporciyan A, Ramirez PT. Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. *Int J Gynecol Cancer* 26(4):801-6, 5/2016. e-Pub 3/2016. PMID: 26937753.
  214. Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearce CL, Zheng W, Painter JN, AOCs Group & Australian Cancer Study (Ovarian Cancer), Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Rudolph A, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, Karlan BY, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MA, Wu X, **Lu KH**, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LC, Kopperud RK, Bjorge L, Kiemeny LA, Massuger LF, Pejovic T, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubinski J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Spiewankiewicz B, Webb PM, Ovarian Cancer Association Consortium. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *Int J Epidemiol* 45(3):884-95, 6/2016. e-Pub 7/2016. PMID: 27401727.
  215. Cuellar-Partida G, Lu Y, Dixon SC, Australian Ovarian Cancer Study, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Høgdall C, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, **Lu KH**, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Stampfer M, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeny LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Blake Gilks C, Gronwald J, Jakubowska A, Lubinski J, Kluz T, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Campbell I, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Goode EL, Schildkraut JM, Pearce CL, Berchuck A, Pharoah PD, Webb PM, Chenevix-Trench G, Risch HA, MacGregor

- S. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. *Hum Genet* 135(7):741-56, 7/2016. e-Pub 4/2016. PMID: PMC4976079.
216. Simmons AR, Clarke CH, Badgwell DB, Lu Z, Sokoll LJ, **Lu KH**, Zhang Z, Bast RC, Skates SJ. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. *Int J Gynecol Cancer* 26(6):1070-7, 7/2016. PMID: PMC4915986.
217. Nebgen DR, Rhodes HE, Hartman C, Munsell MF, **Lu KH**. Abnormal Uterine Bleeding as the Presenting Symptom of Hematologic Cancer. *Obstet Gynecol* 128(2):357-63, 8/2016. PMID: PMC4961605.
218. Ong JS, Cuellar-Partida G, Lu Y, Australian Ovarian Cancer Study, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Anne Doherty J, Anne Rossing M, Chang-Claude J, Eilber U, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Høgdall CK, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, **Lu KH**, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Stampfer M, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeny LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Gilks CB, Gronwald J, Jakubowska A, Lubinski J, Kluz T, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Campbell I, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Risch HA, Goode EL, Schildkraut JM, Pearce CL, Berchuck A, Pharoah PD, Chenevix-Trench G, Gharahkhani P, Neale RE, Webb PM, MacGregor S. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *Int J Epidemiol* 45(5):1619-1630, 10/2016. e-Pub 9/2016. PMID: PMC5100621.
219. Pakish JB, **Lu KH**, Sun CC, Burzawa JK, Greisinger A, Smith FA, Fellman B, Urbauer DL, Soliman PT. Endometrial Cancer Associated Symptoms: A Case-Control Study. *J Womens Health (Larchmt)* 25(11):1187-1192, 11/2016. e-Pub 6/2016. PMID: PMC5116765.
220. Permuth JB, Reid B, Earp M, Chen YA, Monteiro AN, Chen Z, AOCs Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vanderstichele A, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Moysich K, Odunsi K, Goodman MT, Shvetsov YB, Wilkens LR, Thompson PJ, Dörk T, Bogdanova N, Butzow R, Nevanlinna H, Pelttari L, Leminen A, Modugno F, Edwards RP, Ness RB, Kelley J, Heitz F, Karlan B, Lester J, Kjaer SK, Jensen A, Giles G, Hildebrandt M, Liang D, **Lu KH**, Wu X, Levine DA, Bisogna M, Berchuck A, Cramer DW, Terry KL, Tworoger SS, Poole EM, Bandera EV, Fridley B, Cunningham J, Winham SJ, Olson SH, Orlov I, Bjorge L, Kiemeny LA, Massuger L, Pejovic T, Moffitt M, Le N, Cook LS, Brooks-Wilson A, Kelemen LE, Gronwald J, Lubinski J, Wentzensen N, Brinton LA, Lissowska J, Yang H, Hogdall E, Hogdall C, Lundvall L, Pharoah PD, Song H, Campbell I, Eccles D, McNeish I, Whittemore A, McGuire V, Sieh W, Rothstein J, Phelan CM, Risch H, Narod S, McLaughlin J, Anton-Culver H, Ziogas A, Menon U, Gayther S, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Kupryjanczyk J, Dansonka-Mieszkowska A, Schildkraut JM, Cheng JQ, Goode EL, Sellers TA. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. *Oncotarget* 7(45):72381-72394, 11/2016. PMID: PMC5340123.
221. Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, Schmandt R, Yates M, Ramondetta L, **Lu KH**. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A

- window of opportunity study. *Gynecol Oncol* 143(3):466-471, 12/2016. e-Pub 10/2016. PMID: PMC5116402.
222. Armbruster SD, Song J, Bradford A, Carmack CL, **Lu KH**, Basen-Engquist KM. Sexual health of endometrial cancer survivors before and after a physical activity intervention: A retrospective cohort analysis. *Gynecol Oncol* 143(3):589-595, 12/2016. e-Pub 9/2016. PMID: PMC5116408.
223. McCampbell AS, Mittelstadt ML, Dere R, Kim S, Zhou L, Djordjevic B, Soliman PT, Zhang Q, Wei C, Hursting SD, **Lu KH**, Broaddus RR, Walker CL. Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity. *Curr Mol Med* 16(3):252-65, 2016. PMID: 26917264.
224. Burton-Chase AM, Parker WM, Polivka KM, Gritz ER, Amos CI, **Lu KH**, Lynch PM, Rodriguez-Bigas MA, Nancy You Y, Peterson SK. A comparison between Lynch syndrome and sporadic colorectal cancer survivors' satisfaction with their healthcare providers. *Cancer Med* 6(3):698-707, 3/2017. e-Pub 2/2017. PMID: PMC5345658.
225. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KK, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N, AOCs study group, Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KB, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlersen B, Ekici AB, Ellis S, Elvira M, EMBRACE Study, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A, GEMO Study Collaborators, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TV, Harrington PA, Harris HR, Hauke J, HEBON Study, Hein A, Henderson A, Hildebrandt MA, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FB, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T,. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nat Genet*. e-Pub 3/2017. PMID: 28346442.
226. Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, **Lu KH**, Yates MS. Immune Microenvironment in Microsatellite-Unstable Endometrial Cancers: Hereditary or Sporadic Origin Matters. *Clin Cancer Res*. e-Pub 3/2017. PMID: 28264871.
227. Gershenson DM, Bodurka DC, Coleman RL, **Lu KH**, Malpica A, Sun CC. Hormonal Maintenance Therapy for Women with Low-Grade Serous Cancer of the Ovary or Peritoneum. *J Clin Oncol* 35(10):1103-1111, 4/2017. e-Pub 2/2017. PMID: PMC5455356.
228. Suidan RS, He W, Sun CC, Zhao H, Fleming ND, Ramirez PT, Soliman PT, Westin SN, **Lu KH**, Giordano SH, Meyer LA. Impact of body mass index and operative approach on surgical morbidity and costs in women with endometrial carcinoma and hyperplasia. *Gynecol Oncol* 145(1):55-60, 4/2017. e-Pub 1/2017. PMID: 28131529.

229. Ring KL, Yates MS, Schmandt R, Onstad M, Zhang Q, Celestino J, Kwan SY, **Lu KH**. Endometrial Cancers with Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition. *Int J Gynecol Cancer* 27(5):854-862, 6/2017. PMID: 28574929. PMCID: PMC5438270.
230. Suidan RS, He W, Sun CC, Zhao H, Ramondetta LM, Badgwell BD, Bodurka DC, **Lu KH**, Giordano SH, Meyer LA. Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. *Int J Gynecol Cancer*. e-Pub 6/2017. PMID: 28574929.
231. Skates SJ, Greene MH, Buys SS, Mai PL, Brown P, Piedmonte M, Rodriguez G, Schorge JO, Sherman M, Daly MB, Rutherford T, Brewster WR, O'Malley DM, Partridge E, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek S, Davidson SA, Edwards R, Elg SA, Wakeley K, Phillips KA, Armstrong D, Horowitz I, Fabian CJ, Walker J, Sluss PM, Welch W, Minasian L, Horick NK, Kasten CH, Nayfield S, Alberts D, Finkelstein DM, **Lu KH**. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. *Clin Cancer Res* 23(14):3628-3637, 7/2017. e-Pub 1/2017. PMID: 28143870.
232. Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF, Fleming ND, Levenback C, Frumovitz M, Ramirez PT, **Lu KH**. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. *Gynecol Oncol* 146(2):234-239, 8/2017. e-Pub 5/2017. PMID: 28528918.
233. Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, **Lu KH**. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. *Gynecol Oncol* 146(2):399-404, 8/2017. e-Pub 6/2017. PMID: 28610746.
234. Burton-Chase AM, Parker WM, Donato KM, McCormick S, Gritz ER, Amos CI, **Lu KH**, Lynch PM, Rodriguez-Bigas MA, Nancy You Y, Peterson SK. Health-related quality of life in colorectal cancer survivors: are there differences between sporadic and hereditary patients? *J Patient Rep Outcomes* 2(1):21, 2017. e-Pub 5/2018. PMCID: PMC5934923.
235. Iglesias DA, Zhang Q, Celestino J, Sun CC, Yates MS, Schmandt RE, **Lu KH**. Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN. *Oncology* 92(2):109-114, 2017. e-Pub 12/2016. PMID: PMC5285472.
236. Gunther JR, Christensen EN, Allen PK, Ramondetta LM, Jhingran A, Fleming ND, Euscher ED, **Lu KH**, Eifel PJ, Klopp AH. Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma. *Int J Gynecol Cancer* 28(1):114-121, 1/2018. PMID: 28930812.
237. Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, **Lu KH**, Ramirez PT, Ramondetta L, Bodurka DC, Westin SN. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia with the Levonorgestrel-Releasing Intrauterine Device. *Obstet Gynecol* 131(1):109-116, 1/2018. PMID: PMC5739955.
238. Zhang Y, Coletta AM, Allen PK, Parikh AM, Cox-Mattin M, Meyer LA, Sun CC, Basen-Engquist KM, **Lu KH**, Klopp AH. Perirenal Adiposity is Associated with Lower Progression-Free Survival from Ovarian Cancer. *Int J Gynecol Cancer* 28(2):285-292, 2/2018. PMID: PMC5921903.
239. Hillman RT, Chisholm GB, **Lu KH**, Futreal PA. Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer. *J Natl Cancer Inst* 110(3), 3/2018. PMID: 29584920.
240. Yan F, Thall PF, **Lu KH**, Gilbert MR, Yuan Y. Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. *Ann Oncol* 29(3):694-699, 3/2018. PMID: PMC5888967.

241. Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W, Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Jung AY, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, du Bois A, Harter P, Schwaab I, Karlan BY, Lester J, Orsulic S, Rimel BJ, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MAT, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LCV, Kopperud RK, Bjorge L, Kiemeny LA, Massuger LFAG, Pejovic T, Bruegl A, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubinski J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittimore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzylowska A, Rzepecka IK, Webb PM, Ovarian Cancer Association Consortium. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. *Br J Cancer* 118(8):1123-1129, 4/2018. e-Pub 3/2018. PMID: 29555990.
242. Armbruster SD, Song J, Gatus L, **Lu KH**, Basen-Engquist KM. Endometrial cancer survivors' sleep patterns before and after a physical activity intervention: A retrospective cohort analysis. *Gynecol Oncol* 149(1):133-139, 4/2018. e-Pub 2/2018. PMCID: PMC5915323.
243. Du D, Ma W, Yates MS, Chen T, **Lu KH**, Lu Y, Weinstein JN, Broaddus RR, Mills GB, Liu Y. Predicting high-risk endometrioid carcinomas using proteins. *Oncotarget* 9(28):19704-19715, 4/2018. e-Pub 4/2018. PMCID: PMC5929419.
244. Bednar EM, Walsh MT, Baker E, Muse KI, Oakley HD, Krukenberg RC, Dresbold CS, Jenkinson SB, Eppolito AL, Teed KB, Klein MH, Morman NA, Bowdish EC, Russ P, Wise EE, Cooper JN, Method MW, Henson JW, Grainger AV, Arun BK, **Lu KH**. Creation and Implementation of an Environmental Scan to Assess Cancer Genetics Services at Three Oncology Care Settings. *J Genet Couns*. e-Pub 5/2018. PMCID: PMC6240000.
245. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo SH, Thomassen M, Weitzel JN, Chan TL, Couch FJ, Goldgar DE, Kruse TA, Palmero EI, Park SK, Torres D, van Rensburg EJ, McGuffog L, Parsons MT, Leslie G, Aalfs CM, Abugattas J, Adlard J, Agata S, Aittomäki K, Andrews L, Andrulis IL, Arason A, Arnold N, Arun BK, Asseryanis E, Auerbach L, Azzollini J, Balmaña J, Barile M, Barkardottir RB, Barrowdale D, Benitez J, Berger A, Berger R, Blanco AM, Blazer KR, Blok MJ, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caldes T, Caliebe A, Caligo MA, Campbell I, Caputo SM, Chiquette J, Chung WK, Claes KBM, Collée JM, Cook J, Davidson R, de la Hoya M, De Leeneer K, de Pauw A, Delnatte C, Diez O, Ding YC, Ditsch N, Domchek SM, Dorfling CM, Velazquez C, Dworniczak B, Eason J, Easton DF, Eeles R, Ehrencrona H, Ejlertsen B, EMBRACE, Engel C, Engert S, Evans DG, Faivre L, Feliubadaló L, Ferrer SF, Foretova L, Fowler J, Frost D, Galvão HCR, Ganz PA, Garber J, Gauthier-Villars M, Gehrig A, GEMO Study Collaborators, Gerdes AM, Gesta P, Giannini G, Giraud S, Glendon G, Godwin AK, Greene MH, Gronwald J, Gutierrez-Barrera A, Hahnen E, Hauke J, HEBON, Henderson A, Hentschel J, Hogervorst FBL, Honisch E, Imyanитov EN, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Vijai J, Kaczmarek K, Karlan BY, Kast K, Investigators K, Kim SW, Konstantopoulou I, Korach J, Laitman Y, Lasa A, Lasset C, Lázaro C, Lee A, Lee MH,

- Lester J, Lesueur F, Liljegren A, Lindor NM, Longy M, Loud JT, Lu KH, Lubinski J, Machackova E, Manoukian S, Mari V, Martínez-Bouzas C, Matrai Z, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Mickys U, Miller A, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Neuhausen SL, Nevanlinna H, Ngeow J, Nguyen HP, Niederacher D, Nielsen HR, Nielsen FC, Nussbaum RL, Offit K, Öfverholm A, Ong KR, Osorio A, Papi L, Papp J, Pasini B, Pedersen IS, Peixoto A, Peruga N, Peterlongo P. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Hum Mutat* 39(5):593-620, 5/2018. e-Pub 3/2018. PMID: PMC5903938.
246. Yeung TL, Sheng J, Leung CS, Li F, Kim J, Ho SY, Matzuk MM, **Lu KH**, Wong STC, Mok SC. Systematic Identification of Druggable Epithelial-Stromal Crosstalk Signaling Networks in Ovarian Cancer. *J Natl Cancer Inst.* e-Pub 5/2018. PMID: 29860390.
247. Hillman RT, Celestino J, Terranova C, Beird HC, Gumbs C, Little L, Nguyen T, Thornton R, Tippen S, Zhang J, **Lu KH**, Gershenson DM, Rai K, Broaddus RR, Futreal PA. KMT2D/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary. *Nat Commun* 9(1):2496, 6/2018. e-Pub 6/2018. PMID: PMC6021426.
248. Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, Sun CC, Chisholm GB, **Lu KH**. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. *Gynecol Oncol* 150(1):79-84, 7/2018. e-Pub 5/2018. PMID: 29735278.
249. Suidan RS, Sun CC, Cantor SB, Mariani A, Soliman PT, Westin SN, **Lu KH**, Giordano SH, Meyer LA. Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis. *Obstet Gynecol* 132(1):52-58, 7/2018. e-Pub 6/2018. PMID: 29889752.
250. Meyer LA, Lasala J, Iniesta MD, Nick AM, Munsell MF, Shi Q, Wang XS, Cain KE, **Lu KH**, Ramirez PT. Effect of an Enhanced Recovery After Surgery Program on Opioid Use and Patient-Reported Outcomes. *Obstet Gynecol* 132(2):281-290, 8/2018. PMID: PMC6245646.
251. Yates MS, Coletta AM, Zhang Q, Schmandt RE, Medepalli M, Nebgen D, Soletsky B, Milbourne A, Levy E, Fellman B, Urbauer D, Yuan Y, Broaddus RR, Basen-Engquist K, **Lu K**. Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. *Cancer Prev Res (Phila)* 11(8):477-490, 8/2018. e-Pub 5/2018. PMID: PMC6072574.
252. Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G, Australian Ovarian Cancer Study Group, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, Chang-Claude J, Behrens S, Moysich KB, Cannioto R, Lele S, Odunsi K, Goodman MT, Shvetsov YB, Thompson PJ, Wilkens LR, Dörk T, Antonenkova N, Bogdanova N, Hillemanns P, Runnebaum IB, du Bois A, Harter P, Heitz F, Schwaab I, Butzow R, Pelttari LM, Nevanlinna H, Modugno F, Edwards RP, Kelley JL, Ness RB, Karlan BY, Lester J, Orsulic S, Walsh C, Kjaer SK, Jensen A, Cunningham JM, Vierkant RA, Giles GG, Bruinsma F, Southey MC, Hildebrandt MAT, Liang D, **Lu K**, Wu X, Sellers TA, Levine DA, Schildkraut JM, Iversen ES, Terry KL, Cramer DW, Tworoger SS, Poole EM, Bandera EV, Olson SH, Orlow I, Vestrheim Thomsen LC, Bjorge L, Krakstad C, Tangen IL, Kiemeny LA, Aben KKH, Massuger LFAG, van Altena AM, Pejovic T, Bean Y, Kellar M, Cook LS, Le ND, Brooks-Wilson A, Gronwald J, Cybulski C, Jakubowska A, Lubinski J, Wentzensen N, Brinton LA, Lissowska J, Hogdall E, Engelholm SA, Hogdall C, Lundvall L, Nedergaard L, Pharoah PDP, Dicks E, Song H, Tyrer JP, McNeish I, Siddiqui N, Carty K, Glasspool R, Paul J, Campbell IG, Eccles D, Whittemore AS, McGuire V, Rothstein JH, Sieh W, Narod SA, Phelan CM, McLaughlin JR, Risch HA, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Gentry-Maharaj A, Ramus SJ, Wu AH, Pearce CL, Lee AW, Pike MC, Kupryjanczyk J, Podgorska A, Plisiecka-Halasa J, Sawicki W, Goode EL, Berchuck A, Ovarian Cancer Association Consortium. rs495139 in

- the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *Int J Mol Sci* 19(9), 8/2018. e-Pub 8/2018. PMID: PMC6163881.
253. Fleming ND, Nick AM, Coleman RL, Westin SN, Ramirez PT, Soliman PT, Fellman B, Meyer LA, Schmeler KM, **Lu KH**, Sood AK. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. *Obstet Gynecol* 132(3):545-554, 9/2018. PMID: PMC6105510.
254. Meyer LA, He W, Sun CC, Zhao H, Wright AA, Suidan RS, Dottino J, Alejandro Rauh-Hain J, **Lu KH**, Giordano SH. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness. *Gynecol Oncol* 150(3):451-459, 9/2018. e-Pub 6/2018. PMID: 29961559.
255. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, **Lu KH**, Westin SN. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. *Gynecol Oncol* 151(2):374-380, 11/2018. e-Pub 9/2018. PMID: PMC6235625.
256. Taylor JS, He W, Harrison R, Zhao H, Sun CC, **Lu KH**, Giordano SH, Meyer LA. Disparities in treatment and survival among elderly ovarian cancer patients. *Gynecol Oncol* 151(2):269-274, 11/2018. e-Pub 9/2018. PMID: 30253875.
257. Yeung TL, Tsai CC, Leung CS, Au Yeung CL, Thompson MS, **Lu KH**, Freedman RS, Birrer MJ, Wong KK, Mok SC. ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. *Cancers (Basel)* 10(12), 11/2018. e-Pub 11/2018. PMID: 30469497.
258. Parchem JG, Kanasaki K, Kanasaki M, Sugimoto H, Xie L, Hamano Y, Lee SB, Gattone VH, Parry S, Strauss JF, Garovic VD, McElrath TF, **Lu KH**, Sibai BM, LeBleu VS, Carmeliet P, Kalluri R. Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice. *J Clin Invest* 128(11):5008-5017, 11/2018. e-Pub 10/2018. PMID: PMC6205389.
259. Kurnit KC, Previs RA, Soliman PT, Westin SN, Klopp AH, Fellman BM, **Lu KH**, Ramondetta LM, Fleming ND. Prognostic factors impacting survival in early stage uterine carcinosarcoma. *Gynecol Oncol*. e-Pub 11/2018. PMID: 30414738.
260. Earp M, Tyrer JP, Winham SJ, Lin HY, Chornokur G, Dennis J, Aben KKH, Anton-Culver H, Antonenkova N, Bandera EV, Bean YT, Beckmann MW, Bjorge L, Bogdanova N, Brinton LA, Brooks-Wilson A, Bruinsma F, Bunker CH, Butzow R, Campbell IG, Carty K, Chang-Claude J, Cook LS, Cramer DW, Cunningham JM, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles DM, Edwards RP, Ekici AB, Fasching PA, Fridley BL, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Hogdall CK, Høgdall E, Hosono S, Iversen ES, Jakubowska A, Jensen A, Ji BT, Jung AY, Karlan BY, Kellar M, Kiemeny LA, Kiong Lim B, Kjaer SK, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lele S, Lester J, Levine DA, Li Z, Liang D, Lissowska J, **Lu K**, Lubinski J, Lundvall L, Massuger LFAG, Matsuo K, McGuire V, McLaughlin JR, McNeish I, Menon U, Milne RL, Modugno F, Moysich KB, Ness RB, Nevanlinna H, Odunsi K, Olson SH, Orlow I, Orsulic S, Paul J, Pejovic T, Peltari LM, Permuth JB, Pike MC, Poole EM, Rosen B, Rossing MA, Rothstein JH, Runnebaum IB, Rzepecka IK, Schernhammer E, Schwaab I, Shu XO, Shvetsov YB, Siddiqui N, Sieh W, Song H, Southey MC, Spiewankiewicz B, Sucheston-Campbell L, Tangen IL, Teo SH, Terry KL, Thompson PJ, Thomsen L, Tworoger SS, van Altena AM, Vergote I, Vestrheim Thomsen LC, Vierkant RA, Walsh CS, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wicklund KG, Wilkens LR, Woo YL, Wu AH, Wu X, Xiang YB, Yang H, Zheng W, Ziogas A, Lee AW, Pearce CL, Berchuck A, Schildkraut JM, Ramus SJ, Monteiro ANA, Narod SA, Sellers TA, Gayther SA, Kelemen LE, Chenevix-Trench G, Risch HA, Pharoah PDP, Goode

- EL, Phelan CM. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS One* 13(7): e0197561, 2018. e-Pub 7/2018. PMID: PMC6034790.
261. Bednar EM, Sun CC, Camacho B, Terrell J, Rieber AG, Ramondetta LM, Freedman RS, **Lu KH**. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. *Gynecol Oncol* 152(2):328-333, 2/2019. e-Pub 12/2018. PMID: PMC6358478.
262. Skubitz APN, Boylan KLM, Geschwind K, Cao Q, Starr TK, Geller MA, Celestino J, Bast RC, **Lu KH**, Koopmeiners JS. Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection. *Cancer Prev Res (Phila)*. e-Pub 2/2019. PMID: 30709840.
263. Meyer LA, Shi Q, Lasala J, Iniesta MD, Lin HK, Nick AM, Williams L, Sun C, Wang XS, **Lu KH**, Ramirez PT. Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery. *Gynecol Oncol* 152(3):501-508, 3/2019. PMID: PMC6422048.
264. Suidan RS, He W, Sun CC, Zhao H, Smith GL, Klopp AH, Fleming ND, **Lu KH**, Giordano SH, Meyer LA. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer. *Gynecol Oncol* 152(3):439-444, 3/2019. PMID: 30876486.
265. Sun CC, Meyer LA, Daniels MS, Bodurka DC, Nebgen DR, Burton-Chase AM, **Lu KH**, Peterson SK. Women's preferences for cancer risk management strategies in Lynch syndrome. *Gynecol Oncol* 152(3):514-521, 3/2019. PMID: PMC6422049.
266. Simmons AR, Fourkala EO, Gentry-Maharaj A, Ryan A, Sutton MN, Baggerly K, Zheng H, **Lu KH**, Jacobs I, Skates S, Menon U, Bast RC. Complementary longitudinal serum biomarkers to CA125 for early detection of ovarian cancer. *Cancer Prev Res (Phila)*. e-Pub 4/2019. PMID: 30967390.
267. Hinchcliff EM, Bednar EM, **Lu KH**, Rauh-Hain JA. Disparities in gynecologic cancer genetics evaluation. *Gynecol Oncol* 153(1):184-191, 4/2019. e-Pub 1/2019. PMID: PMC6430691.
268. Suidan RS, He W, Sun CC, Zhao H, Rauh-Hain JA, Fleming ND, **Lu KH**, Giordano SH, Meyer LA. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. *Am J Obstet Gynecol*. e-Pub 4/2019. PMID: 30965052.
269. Dottino JA, Moss HA, **Lu KH**, Secord AA, Havrilesky LJ. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis. *Obstet Gynecol* 133(4):795-802, 4/2019. PMID: 30870286.
270. Chapman BV, Swanick CW, Ning MS, Allen PK, Soliman PT, Westin SN, Pardeshi V, Broaddus RR, **Lu KH**, Jhingran A, Eifel PJ, Klopp AH. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. *Gynecol Oncol* 154(1):22-28, 7/2019. e-Pub 5/2019. PMID: 31109659.
271. Rayes N, Bowen DJ, Coffin T, Nebgen D, Peterson C, Munsell MF, Gavin K, Lechner R, Crase J, Polinsky D, Romero I, Blank SV, Levine DA, Norquist BM, Swisher EM, **Lu KH**. MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing. *BMC Cancer* 19(1):648, 7/2019. e-Pub 7/2019. PMID: PMC6604336.
272. Dottino JA, He W, Sun CC, Zhao H, Fu S, **Lu KH**, Meyer LA. Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes. *Gynecol Oncol* 154(2):405-410, 8/2019. e-Pub 6/2019. PMID: 31208738.

273. Creutzberg CL, **Lu KH**, Fleming GF. Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease. *J Clin Oncol* 37(27):2490-2500, 9/2019. e-Pub 8/2019. PMID: 31403860.
274. Friebel TM, Andrulis IL, Balmaña J, Blanco AM, Couch FJ, Daly MB, Domchek SM, Easton DF, Foulkes WD, Ganz PA, Garber J, Glendon G, Greene MH, Hulick PJ, Isaacs C, Jankowitz RC, Karlan BY, Kirk J, Kwong A, Lee A, Lesueur F, **Lu KH**, Nathanson KL, Neuhausen SL, Offit K, Palmero EI, Sharma P, Tischkowitz M, Toland AE, Tung N, van Rensburg EJ, Vega A, Weitzel JN, Collaborators GS, Hoskins KF, Maga T, Parsons MT, McGuffog L, Antoniou AC, Chenevix-Trench G, Huo D, Olopade OI, Rebbeck TR. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. *Hum Mutat* 40(10):1781-1796, 10/2019. e-Pub 7/2019. PMCID: PMC6764847.
275. Coletta AM, Peterson SK, Gatus LA, Krause KJ, Schembre SM, Gilchrist SC, Pande M, Vilar E, You YN, Rodriguez-Bigas MA, Strong LL, Lynch PM, **Lu KH**, Basen-Engquist K. Energy balance related lifestyle factors and risk of endometrial and colorectal cancer among individuals with lynch syndrome: a systematic review. *Fam Cancer* 18(4):399-420, 10/2019. e-Pub 6/2019. PMID: 31236808.
276. Stewart KI, Chasen B, Erwin W, Fleming N, Westin SN, Dioun S, Frumovitz M, Ramirez PT, **Lu KH**, Wong F, Aloia TA, Soliman PT. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study. *Cancer* 125(19):3347-3353, 10/2019. e-Pub 6/2019. PMCID: PMC6744337.
277. Donato KM, Moore K, Parker WM, Peterson SK, Gritz ER, Amos CI, **Lu KH**, Lynch PM, Rodriguez-Bigas MA, You YN, Burton-Chase AM. Health and lifestyle behaviors in colorectal cancer survivors with and without Lynch syndrome. *J Community Genet* 11(1):59-63, 1/2020. e-Pub 4/2019. PMCID: PMC6962402.
278. Kwan SY, Au-Yeung CL, Yeung TL, Rynne-Vidal A, Wong KK, Risinger JI, Lin HK, Schmandt RE, Yates MS, Mok SC, **Lu KH**. Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) Promotes Uterine Serous Cancer Cell Proliferation and Cell Cycle Progression. *Cancers (Basel)* 12(1), 1/2020. e-Pub 1/2020. PMCID: PMC7016780.
279. Harrison R, Zhao H, Sun CC, Fu S, Armbruster SD, Westin SN, Rauh-Hain JA, **Lu KH**, Giordano SH, Meyer LA. Body mass index and attitudes towards health behaviors among women with endometrial cancer before and after treatment. *Int J Gynecol Cancer* 30(2):187-192, 2/2020. e-Pub 12/2019. PMCID: PMC7307445.
280. Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, **Lu KH**, Coleman RL. Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: A multi-center, single arm, phase II study. *Clin Cancer Res* 26(3):581-587, 2/2020. e-Pub 10/2019. PMCID: PMC7002216.
281. Yang WL, Lu Z, Guo J, Fellman BM, Ning J, **Lu KH**, Menon U, Kobayashi M, Hanash SM, Celestino J, Skates SJ, Bast RC. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer. *Cancer* 126(4):725-736, 2/2020. e-Pub 11/2019. PMCID: PMC6992519.
282. Kobayashi M, Katayama H, Irajizad E, Vykoukal JV, Fahrman JF, Kundnani DL, Yu CY, Cai Y, Hsiao FC, Yang WL, Lu Z, Celestino J, Long JP, Do KA, **Lu KH**, Ladd JJ, Urban N, Bast RC, Hanash SM. Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. *Cancers (Basel)* 12(2), 2/2020. e-Pub 2/2020. PMCID: PMC7072578.
283. McGrail DJ, Garnett J, Yin J, Dai H, Shih DJH, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, **Hu L**, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu KH, Broaddus R, Mills GB, Sahni N, Lin SY. Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. *Cancer Cell* 37(3):371-386.e12, 3/2020. e-Pub 2/2020. PMCID: PMC7337255.

284. Onstad M, Ducie J, Fellman BM, Abu-Rustum NR, Leitao M, Mariani A, Multinu F, **Lu KH**, Soliman P. Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus. *Int J Gynecol Cancer* 30(4):485-490, 4/2020. e-Pub 1/2020. PMID: 31980487.
285. Konstantinopoulos PA, Norquist B, Lacchetti C, Armstrong D, Grisham RN, Goodfellow PJ, Kohn EC, Levine DA, Liu JF, **Lu KH**, Sparacio D, Annunziata CM. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. *J Clin Oncol* 38(11): JCO1902960, 4/2020. e-Pub 1/2020. PMID: 31986064.
286. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, **Lu KH**, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. *Cell Rep* 31(2):107502, 4/2020. PMCID: PMC7234854.
287. Emborgo TS, Saporito D, Muse KI, Barrera AMG, Litton JK, **Lu KH**, Arun BK. Prospective Evaluation of Universal BRCA Testing for Women with Triple-Negative Breast Cancer. *JNCI Cancer Spectr* 4(2): pkaa002, 4/2020. e-Pub 1/2020. PMCID: PMC7083268.
288. Kalachand RD, Stordal B, Madden S, Chandler B, Cunningham J, Goode EL, Ruscito I, Braicu EI, Sehouli J, Ignatov A, Yu H, Katsaros D, Mills GB, **Lu KH**, Carey MS, Timms KM, Kupryjanczyk J, Rzepecka IK, Podgorska A, McAlpine JN, Swisher EM, Bernards SS, O'Riain C, O'Toole S, O'Leary JJ, Bowtell DD, Thomas DM, Prieske K, Joosse SA, Woelber L, Chaudhry P, Häfner N, Runnebaum IB, Hennessy BT. BRCA1 promoter methylation and clinical outcomes in ovarian cancer: an individual patient data meta-analysis. *J Natl Cancer Inst.* e-Pub 5/2020. PMID: 32413141.
289. Au-Yeung CL, Yeung TL, Achreja A, Zhao H, Yip KP, Kwan SY, Onstad M, Sheng J, Zhu Y, Baluya DL, Co NN, Rynne-Vidal A, Schmandt R, Anderson ML, **Lu KH**, Wong STC, Nagrath D, Mok SC. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. *Nat Commun* 11(1):3546, 7/2020. e-Pub 7/2020. PMCID: PMC7363861.
290. Dottino JA, He W, Sun CC, Zhao H, Fu S, Rauh-Hain JA, Suidan RS, **Lu KH**, Giordano SH, Meyer LA. National trends in bowel and upper abdominal procedures in ovarian cancer surgery. *Int J Gynecol Cancer.* e-Pub 7/2020. PMID: 32616627.
291. Hu W, Zhang L, Ferri-Borgogno S, Kwan SY, Lewis KE, Cun HT, Yeung TL, Soliman PT, Tarapore RS, Allen JE, Guan X, **Lu KH**, Mok SC, Au-Yeung CL. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. *Cancers (Basel)* 12(9), 8/2020. e-Pub 8/2020. PMID: 32867127.
292. Slomovitz BM, Chelariu-Raicu A, Schmeler KM, **Lu KH**, Gershenson DM, Wolf J, Coleman RL. Phase 2 study of cetuximab (Erbix) in patients with progressive or recurrent endometrial cancer. *Int J Gynecol Cancer* 30(11):1733-1737, 11/2020. e-Pub 10/2020. PMID: 33020204.
293. Coletta AM, Peterson SK, Gatus LA, Krause KJ, Schembre SM, Gilchrist SC, Arun B, You YN, Rodriguez-Bigas MA, Strong LL, **Lu KH**, Basen-Engquist K. Diet, weight management, physical activity, and Ovarian & Breast Cancer Risk in women with BRCA1/2 pathogenic Germline gene variants: systematic review. *Hered Cancer Clin Pract* 18:5, 2020. e-Pub 3/2020. PMCID: PMC7060535.
294. Glubb DM, Thompson DJ, Aben KKH, Alsulimani A, Amant F, Annibaldi D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjorge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Butzow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen XQ, Chen Z, Cook LS, Cunningham JM, De Vivo I, deFazio A, Doherty JA, Dörk T, du Bois A, Dunning AM,

- Dürst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilias G, Friedenreich CM, Gao B, Gaudet MM, Gawelko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, **Lu KH**, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permut JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron LM, Teo SH, Thompson PJ, Thomsen LCV, Titus L, Tone A, Tumino R, Turman C, Vanderstichele A, Edwards DV, Vergote I, Vierkant RA, Wang Z, Wang-Gohrke S, Webb PM, OPAL Study Group, AOCs Group, White E, Whittemore AS, Winham SJ, Wu X, Wu AH, Yannoukakos D, Spurdle AB, O'Mara TA. Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers. *Cancer Epidemiol Biomarkers Prev* 30(1):217-228, 1/2021. e-Pub 11/2020. PMID: 33144283.
295. Fahrman JF, Irajizad E, Kobayashi M, Vykoukal J, Dennison JB, Murage E, Wu R, Long JP, Do KA, Celestino J, **Lu KH**, Lu Z, Bast RC, Hanash S. A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. *Cancers (Basel)* 13(4), 2/2021. e-Pub 2/2021. PMID: PMC7927060.
296. Hu W, Zhang L, Ferri-Borgogno S, Kwan SY, Lewis KE, Cun HT, Yeung TL, Soliman PT, Tarapore RS, Allen JE, Guan X, **Lu KH**, Mok SC, Au-Yeung CL. Correction: Hu, W., et al. Targeting Dopamine Receptor D2 by Imipridone Suppresses Uterine Serous Cancer Malignant Phenotype. *Cancers* 2020, 12, 2436. *Cancers (Basel)* 13(4), 2/2021. e-Pub 2/2021. PMID: PMC7915108.
297. **Lu KH**, Broaddus RR. Endometrial Cancer. Reply. *N Engl J Med* 384(6):586, 2/2021. PMID: 33567204.
298. How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, **Lu KH**, Yates MS. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. *Cancers (Basel)* 13(5), 2/2021. e-Pub 2/2021. PMID: PMC7956737.
299. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, **Lu KH**, Bodurka DC, Coleman RL, Yates MS. Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial Cancer. *Am J Obstet Gynecol* 224(2):191.e1-191.e15, 2/2021. e-Pub 8/2020. PMID: PMC7855308.
300. Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, **Lu KH**, Coleman RL, Maxwell GL, Sood AK. Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. *Gynecol Oncol* 160(3):777-785, 3/2021. e-Pub 2/2021. PMID: 33563487.
301. Dottino JA, Zhang Q, Loose DS, Fellman B, Melendez BD, Borthwick MS, McKenzie LJ, Yuan Y, Yang RK, Broaddus RR, **Lu KH**, Soliman PT, Yates MS. Endometrial biomarkers in premenopausal obese women: an at-risk cohort. *Am J Obstet Gynecol* 224(3):278.e1-278.e14, 3/2021. e-Pub 8/2020. PMID: PMC7897335.

302. Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, **Lu KH**, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. *Gynecol Oncol* 161(1):56-62, 4/2021. e-Pub 1/2021. PMID: PMC8247119.
303. Nitecki R, Moss HA, Watson CH, Urbauer DL, Melamed A, **Lu KH**, Lipkin SM, Offit K, Rauh-Hain JA, Frey MK. Facilitated cascade testing (FaCT): a randomized controlled trial. *Int J Gynecol Cancer* 31(5):779-783, 5/2021. e-Pub 12/2020. PMID: 33443030.
304. Nitecki R, Melamed A, Gockley AA, Floyd J, Krause KJ, Coleman RL, Matulonis UA, Giordano SH, **Lu KH**, Rauh-Hain JA. Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. *Gynecol Oncol* 161(3):653-659, 6/2021. e-Pub 3/2021. PMID: PMC8164998.
305. Nitecki R, Fleming ND, Fellman BM, Meyer LA, Sood AK, **Lu KH**, Rauh-Hain JA. Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. *Gynecol Oncol* 161(3):660-667, 6/2021. e-Pub 4/2021. PMID: PMC8165031.
306. Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, **Lu KH**, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. *Gynecol Oncol* 162(1):65-71, 7/2021. e-Pub 4/2021. PMID: PMC8287765.
307. Huepenbecker S, Hillman RT, Iniesta MD, Chen T, Cain K, Mena G, Lasala J, Wang XS, Williams L, Taylor JS, **Lu KH**, Ramirez PT, Meyer LA. Impact of a tiered discharge opioid algorithm on prescriptions and patient-reported outcomes after open gynecologic surgery. *Int J Gynecol Cancer* 31(7):1052-1060, 7/2021. e-Pub 6/2021. PMID: PMC8328052.
308. Harrison RF, Fu S, Sun CC, Zhao H, **Lu KH**, Giordano SH, Meyer LA. Patient cost sharing during poly (adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. *Am J Obstet Gynecol* 225(1):68.e1-68.e11, 7/2021. e-Pub 2/2021. PMID: PMC8254740.
309. How JA, Patel S, Fellman B, **Lu KH**, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. *Gynecol Oncol* 162(1):24-31, 7/2021. e-Pub 5/2021. PMID: PMC8222164.
310. Melendez B, Shah S, Jiang Y, Dottino J, Watson E, Pearce H, Borthwick M, Schmandt RE, Zhang Q, Cumpian K, Celestino J, Fellman B, Yuan Y, **Lu KH**, Mikos AG, Yates MS. Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications. *J Control Release* 339:521-530, 11/2021. e-Pub 10/2021. PMID: PMC8650567.
311. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, **Lu KH**, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. *Clin Cancer Res* 27(23):6354-6365, 12/2021. e-Pub 9/2021. PMID: PMC8639651.
312. Yeh LT, Lin CW, **Lu KH**, Hsieh YH, Yeh CB, Yang SF, Yang JS. Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression via the ERK Signaling Pathway. *Int J Mol Sci* 23(1), 1/2022. e-Pub 1/2022. PMID: PMC8745393.
313. Corrigan KL, Yoder A, De B, Lin L, Jhingran A, Joyner MM, Eifel PJ, Colbert LE, **Lu KH**, Klopp AH. Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. *Gynecol Oncol* 164(3):550-557, 3/2022. e-Pub 12/2021. PMID: PMC9257896.

314. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrus IL, Anton-Culver H, Antonenkova NN, Aravatinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, GEMO Study Collaborators, GC-HBOC Study Collaborators, EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, OPAL Study Group, AOCS Group, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, KConFab Investigators, HEBON Investigators, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeny LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, **Lu KH**, Lubinski J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT,. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. *Eur J Hum Genet* 30(3):349-362, 3/2022. e-Pub 1/2022. PMID: PMC8904525.
315. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrus IL, Anton-Culver H, Antonenkova NN, Aravatinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, GEMO Study Collaborators, GC-HBOC Study Collaborators, EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, OPAL Study Group, AOCS Group, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, KConFab Investigators, HEBON Investigators, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeny LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, **Lu KH**, Lubinski J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT,. Correction: Polygenic risk modeling for prediction of

- epithelial ovarian cancer risk. *Eur J Hum Genet* 30(5):630-631, 5/2022. PMID: PMC9090804.
316. Boylan KLM, Petersen A, Starr TK, Pu X, Geller MA, Bast RC, **Lu KH**, Cavallaro U, Connolly DC, Elias KM, Cramer DW, Pejovic T, Skubitz APN. Development of a Multiprotein Classifier for the Detection of Early-Stage Ovarian Cancer. *Cancers (Basel)* 14(13), 6/2022. e-Pub 6/2022. PMID: PMC9264950.
  317. Zhang L, Au-Yeung CL, Huang C, Yeung TL, Ferri-Borgogno S, Lawson BC, Kwan SY, Yin Z, Wong ST, Thomas V, **Lu KH**, Yip KP, Sham JSK, Mok SC. Ryanodine receptor 1-mediated Ca<sup>2+</sup> signaling and mitochondrial reprogramming modulate uterine serous cancer malignant phenotypes. *J Exp Clin Cancer Res* 41(1):242, 8/2022. e-Pub 8/2022. PMID: PMC9373370.
  318. Dholakia J, Lee YW, **Lu KH**, Huh WK, Yamada SD, Fuh KC, Kumar AS, Liang MI, Nair N, Kim KH. Identity-related experiences of Asian American trainees in gynecologic oncology. *Gynecol Oncol Rep* 44:101097, 12/2022. e-Pub 11/2022. PMID: PMC9664478.
  319. Aoun E, Lawson B, Awujo C, Nebgen D, Soletsky BR, Chisholm GB, **Lu KH** (GYN ONC), Nitecki Wilke R. Oncologic outcomes of incidental serous tubal intraepithelial carcinoma and associated high-grade serous carcinoma in high-risk patients undergoing risk-reducing surgery. *Int J Gynecol Cancer* 2024 Nov; In Press PMID:39496390 **IF:4.500**
  320. Faupel-Badger J, Kohaar I, Bahl M, Chan AT, Campbell JD, ding L, De Marzo AM, Maitra A, Merrick DT, Hawk ET, Wistuba II, Ghobrial IM, Lippman SM, **Lu KH** (GYN ONC), Lawler M, Kay NE, Tlsty TD, Rebbeck TR, Srivastava S. Defining precancer: a grand challenge for the cancer community. *Nat Rev Cancer* 2024 Nov; 24: (11) 792-809 PMID: 39354069. **IF: 72.500**
  321. Bednar EM, Nitecki Wilke R, Jorgensen K, Walsh MT, Nutt S, **Lu KH** (GYN ONC), Nóbrega L, De Souza APSD, da Silva Oliveira G, da Cunha Andrade CEM, Purizaca-Rosillo N, Mora P, López Blanco A, Gallardo-Alvarado LN, Cantú-de León D, Rauh-Hain JA. Feasibility of an environmental scan-based approach to collecting information about factors impacting cancer genetics services in Latin American countries. *J Community Genet* 2024 Dec; 15: (6) 681-686 PMID: 39397225. PMID: PMC11645378. **IF: 1.500**
  322. Aoun E, Lawson B, Awujo C, Nebgen D, Soletsky BR, Chisholm GB, **Lu KH** (GYN ONC), Nitecki Wilke R. Oncologic outcomes of incidental serous tubal intraepithelial carcinoma and associated high-grade serous carcinoma in high-risk patients undergoing risk-reducing surgery. *Int J Gynecol Cancer* 2025 Jan; In Press PMID: 39496390. **IF: 4.500**
  323. Ring KL, Mills AM, Howitt BE, Grisham RN, Euscher ED, Kim HS, Klopp AH, Kolin DL, McCluggage WG, Mirkovic J, Park KJ, Aoun E, Awujo C, Son J, Mok SC, Ferri-Borgogno S, Hong DS, Hoang L, Jazaeri AA, How JA, **Lu KH** (GYN ONC). Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics. *Gynecol Oncol* 2025 Jun; 197: 57-65 PMID: 40279981. **IF 4.500**
  324. Gootzen TA, Steenbeek MP, van Gelder MMHJ, van Bommel MHD, Timmer-Bonte JNH, Kets CM, Wilke RN, Swisher EM, Norquist BM, **Lu KH** (HOB), Hermens RPMG, de Hullu JA. Impact of breast cancer history on decision-making for ovarian cancer risk-reducing surgery in the TUBA-WISP-II study. *Am J Obstet Gynecol* 2025 Dec; 233: (6) 638.e1-638.e13 PMID: 40532962. **IF: 8.400**
  325. Adjei NN, Yeh PG, Haas A, Sun CC, Zhao H, Stone R, Roche KL, **Lu KH** (HOB), Toumazis I, Meyer LA. Opportunistic salpingectomy during gynecologic and non-gynecologic abdominopelvic procedures for ovarian cancer primary prevention: a cost-effectiveness analysis. *Int J Gynecol Cancer* 2025 Dec 102884- In Press PMID: 41605705. **IF: 4.700**
  326. Mills AM, Euscher ED, McCluggage WG, Mirkovic J, Park KJ, Kolin DL, Hoang L, Kim HS, How JA, **Lu KH** (GYN ONC), Ring KL, Howitt BE. Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance

#### Invited Articles

1. Tuncer ZS, Bernstein MR, Goldstein DP, **Lu KH**, Berkowitz RS. Outcome of pregnancies occurring within 1 year of hydatidiform mole. *Obstet Gynecol* 94(4):588-90, 10/1999. PMID: 10511364.
2. **Lu KH**, Goldstein DP, Bernstein MR, Berkowitz RS. Clinical decisions in gestational trophoblastic diseases. *Contemporary OB/GYN*, 1999.
3. **Lu KH**, Goldstein DP, Bernstein MR, Berkowitz RS. Managing molar pregnancies. *OBG Management*, 1999.
4. **Lu KH**, Edelson MI, Rodabaugh KJ, Wertheim I, Colitti CV, Bell DA, Welch WR, Berkowitz RS, Mok SC. Pathogenesis of borderline ovarian tumors. *Proc AACR* 40:760-761, 1999.
5. **Lu KH**, Burke TW. Early cervical cancer. *Current Treatment Options in Oncology* 1(2):147-55, 6/2000. PMID: 12057052.
6. **Lu KH**, Gershenson DM. Management of borderline ovarian tumors. *Contemporary OB/GYN* 45:89-100, 2000.
7. **Lu KH**, Broaddus RR. Gynecological tumors in hereditary nonpolyposis colorectal cancer: We know they are common-now what? *Gynecol Oncol* 82:221-2, 2001. PMID: 11531270.
8. Bast Jr RC, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, **Lu K**, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: Promise and reality. *Cancer Treat Res* 107:61-97, 2002. PMID: 11775462.
9. **Lu KH**. More Communication Needed to Address Gyn Cancer Risks in Breast Cancer Patients. *MAMM*(July/August): p 19, 2003.
10. **Lu KH**. The Levine/Gemignani Article Reviewed (Prophylactic Surgery in Hereditary Breast/Ovarian Cancer Syndrome). *Oncology* 17:951-952, 2003.
11. Broaddus RR, **Lu KH**. Future challenges in clinical and translational research for endometrial cancer. *Int J Gyn Cancer* 15:398, 2005.
12. **Lu, K**, Broaddus R. Gynecologic cancers in Lynch Syndrome/HNPCC. *Familial Cancer* 4:249-254, 2005.
13. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, **Lu K**. New tumor markers: CA126 and beyond. *Int J Gynl Cancer* 3:274-81, 2005.
14. **Lu KH**. Update in Gynecologic Cancer. *OBG Management*, 2005.
15. **Lu KH**, Gershenson DM. Update on the management of ovarian germ cell tumors. *J Reprod Med* 50:417-25, 2005. PMID: 16050566.
16. **Lu KH**. Update in Gynecologic Cancer. *OBG Management*, 2006.
17. Broaddus RR, **Lu KH**. Women with HNPCC: a target population for the chemoprevention of gynecologic cancers. *Front Biosci* 11:2077-80, 2006. PMID: 16720294.
18. **Lu KH**. "Best Health", Endometrial Cancer Related Links. *U.S. News & World Report*, 1/2007.
19. **Lu KH**. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. *Fam Cancer* 7(1):53-8, 7/2007.
20. Soliman PT, **Lu K**. Endometrial cancer associated with defective DNA mismatch repair. *Obstet Gynecol Clin North Am* 34:701-15, 2007.
21. Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, **Lu K**, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. Prevention and early detection of ovarian cancer: mission impossible? *Cancer Res* 174:91-100, 2007.
22. **Lu KH**. Update in Gynecologic Cancer. *OBG Management*, 2007.

23. Schmeler KM, **Lu KH**. Gynecologic cancers associated with Lynch syndrome/HNPCC. *Clin Transl Oncol* 10(6):313-7, 6/2008. PMID: 18558577.
24. Meyer LA, Westin SN, **Lu KH**, Milam MR. Genetic polymorphisms and endometrial cancer risk. *Expert Rev Anticancer Ther* 8(7):1159-67, 7/2008. PMID: 18588460.
25. Meyer LA, Broaddus RR, **Lu KH**. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. *Cancer Control* 16(1):14-22, 1/2009. PMID: 19078925.
26. **Lu KH**. Management of Early-Stage Endometrial Cancer. *Semin Oncol* 36(2):137-44, 4/2009. PMID: 19332248.
27. **Lu KH**, Yates MS, Mok SC. The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention. *Cancer Prev Res (Phila Pa)* 2(9):773-5, 9/2009. e-Pub 9/2009. PMID: 19737981.
28. **Lu KH**. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: Missed opportunities. *Obstet Gynecol* 116(No. 2, Part 1):441, 8/2010.
29. Daniels MS, Burzawa JK, Brandt AC, Schmeler KM, **Lu KH**. A clinical perspective on genetic counseling and testing during end-of-life care for women with recurrent progressive ovarian cancer: opportunities and challenges. *Fam Cancer* 10(2):193-7, 6/2011. e-Pub 1/2011. PMID: PMC4286250.
30. Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. *Am J Obstet Gynecol* 205(6):518-25, 12/2011. e-Pub 6/2011. PMID: PMC4264838.
31. Holman LL, **Lu KH**. Genetic risk and gynecologic cancers. *Hematol Oncol Clin North Am* 26(1):13-29, 2/2012. PMID: PMC5134904.
32. Trimble CL, Method M, Leitao M, Lu K, Ioffe O, Hampton M, Higgins R, Higgins R, Zaino R, Mutter GL. Management of endometrial precancers. *Obstet Gynecol* 122(5):160-1175, 2012. PMID: PMC4286250.
33. Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. *Fam Cancer* 12(2):273-7, 6/2013. PMID: PMC3820416.
34. Daniels MS, **Lu KH**. Clearer Picture of PMS2-Associated Lynch Syndrome Is Emerging. *J Clin Oncol* 33(4):299-300, 2/2015. e-Pub 12/2014. PMID: 25534383.
35. Olson SH, De Vivo I, Setiawan VW, **Lu KH**. Symposium on advances in endometrial cancer epidemiology and biology. *Gynecol Oncol*. e-Pub 7/2015. PMID: 26232339.
36. Daniels MS, **Lu KH**. Genetic predisposition in gynecologic cancers. *Semin Oncol* 43(5):543-547, 10/2016. e-Pub 9/2016. PMID: 27899185.
37. Onstad MA, Schmandt RE, **Lu KH**. Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment. *J Clin Oncol* 34(35):4225-4230, 12/2016. e-Pub 11/2016. PMID: 27903150.
38. Corzo C, Iniesta MD, Patrono MG, **Lu KH**, Ramirez PT. Role of Fallopian Tubes in the Development of Ovarian Cancer. *J Minim Invasive Gynecol* 24(2):230-234, 2/2017. e-Pub 12/2016. PMID: 28007588.
39. Lewis KE, **Lu KH**, Klimczak AM, Mok SC. Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision. *Cancers (Basel)* 10(2), 2/2018. e-Pub 2/2018. PMID: PMC5836089.
40. Nebgen DR, **Lu KH**, Bast RC. Novel Approaches to Ovarian Cancer Screening. *Curr Oncol Rep* 21(8):75, 7/2019. e-Pub 7/2019. PMID: PMC6662655.
41. Kurnit KC, **Lu KH**, Westin SN. Rapidly Changing Landscape of Fallopian Tube Carcinoma. *J Oncol Pract* 15(7):383-384, 7/2019. e-Pub 7/2019. PMID: 31283416.
42. Zhang L, Kwan SY, Wong KK, Solaman PT, **Lu KH**, Mok SC. Pathogenesis and Clinical Management of Uterine Serous Carcinoma. *Cancers (Basel)* 12(3), 3/2020. e-Pub 3/2020. PMID: PMC7140057.

43. Bast RC, Lu Z, Han CY, **Lu KH**, Anderson KS, Drescher CW, Skates S. Biomarkers and Strategies for Early Detection of Ovarian Cancer. *Cancer Epidemiol Biomarkers Prev.* e-Pub 10/2020. PMID: 33051337.
44. **Lu KH**, Broaddus RR. Endometrial Cancer. *N Engl J Med* Chapter 11(21):109-118, 11/2020. PMID: 33207095.

### Editorials

1. **Lu KH**. Gynecologic tumors in hereditary nonpolyposis colorectal cancer: We know they are common-now what? *Gynecologic Oncology* 82:221-2, 2001.
2. **Lu KH**, Kauff ND. Does a BRCA mutation plus tamoxifen equal hysterectomy? *Gynecol Oncol* 104(1)(1):3-4, 1/2007. PMID: 17222708.
3. Wood ME, **Lu KH**, Wollins DS, Hughes KS. Reply to A.S. Sie et al, K. Hemminki et al, and J. Larsen Haidle. *J Clin Oncol* 32(29):3346-7, 10/2014. e-Pub 9/2014. PMID: 25185101.
4. Daniels MS, **Lu KH**. Reply to D. Braun et al. *J Clin Oncol* 32(32):3683, 11/2014. e-Pub 9/2014. PMID: 25199758.
5. **Lu KH**, Ring KL. One size may not fit all: the debate of universal tumor testing for Lynch syndrome. *Gynecol Oncol* 137(1):2-3, 4/2015. PMID: 25818039.
6. Dottino JA, **Lu KH**. Towards value-based universal Lynch syndrome identification in endometrial cancer patients. *Gynecol Oncol* 143(3):451-452, 12/2016. PMID: 27865420.
7. Lu KH. Screening for Ovarian Cancer in Asymptomatic Women. *JAMA* 319(6):557-558, 2/2018. PMID: 29450509.
8. Cun HT, Lu KH. Unanswered Questions in High-Risk Women Undergoing Risk-Reducing Salpingo-oophorectomy. *Obstet Gynecol* 135(3):495-497, 3/2020. PMID: 32028509.

### Other Articles

1. **Lu, KH**, JE Garber, DW Cramer, WR Welch, J Niloff, D Schrag, RS Berkowitz, M G Muto. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. *Journal of Clinical Oncology/Classic Papers and Current Comments* 18(14):2728-2732, 2000.

### Abstracts

1. Dottino JA, Jiang Y, Shah S, Celestino J, Watson E, Zhang Q, Chisholm G, Burks J, Mikos A, **Lu KH**, Yates M. Novel intrauterine polymer system delivers everolimus atbiologically active levels in rats. SGO 2018 Annual Meeting, Scientific Plenary, 2018.
2. Amaria RN, Bernatchez C, Forget MA, Haymaker CL, Conley AP, Livingston JA, Varadhachary GR, Javle MM, Maitra A, David Tzeng CW, Hinchcliff E, Bayer V, Gasior Y, Hilton T, Celestino J, Rangel KM, Yuan Y, **Lu KH**, Hwu P, Jazaeri AA. Adoptive transfer of tumor-infiltrating lymphocytes in patients with sarcomas, ovarian, and pancreatic cancers. 2019 ASCO Annual Meeting, 2019.
3. Taylor JS, Miller JF, Ballard EK, Blanco TK, Brown KL, Byrd CC, Holloway A, Smith A, Park A, Cain K, Marten C, Finch R, Nguyen V, Fleming D, Levenback CF, **Lu KH**, Schmelzer KM. An initiative to improve mortality index in gynecologic oncology. 2019 ASCO Quality Care Symposium, 2019.
4. Harrison R, Cantor SB, Villanueva M, Suidan RS, Sun CC, Rauh-Hain JA, Westin SN, Fleming ND, Sood AK, **Lu KH**, Meyer L. Cost-effectiveness analysis of laparoscopic disease assessment in ovarian cancer. 2019 ASCO Annual Meeting, 2019.
5. Hinchcliff E, Peng W, Bayer V, Haymaker CL, Huang SY, Sheth R, Westin SN, **Lu KH**, Hwu P, Jazaeri AA. Phase Ib clinical investigation of intraperitoneal ipilimumab and nivolumab in patients with peritoneal carcinomatosis due to gynecologic malignancy. 2019 ASCO Annual Meeting, 2019.
6. Swisher EM, Rayes N, Bowen D, Peterson CB, Coffin T, Norquist B, Gavin K, Polinsky D, Crase J, Bakkum-Gamez JN, Blank SV, Munsell MF, Nebgen DR, Pradeep H, Law S,

Olopade OI, Zhou A, Levine DA, D'Andrea AD, **Lu KH**. Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk. 2020 ASCO Virtual Scientific Program, 2020.

### **Book Chapters**

1. Burke TW, **Lu KH**. Surgical Treatment of Invasive Cervical Cancer. In: ACS Atlas of Clinical Oncology: Cancer of the Female Lower Genital Tract. B.C. Decker Inc., 133-145, 2001.
2. **Lu KH**, Gershenson DM, Poynor EA, Sabbatini PJ. Germ-cell and ovarian sex cord-stromal tumors. In: MSKCC-MDACC Handbook of Gynecologic Oncology. Martin Dunitz Publishers, Ltd., Pg 271-82, Chapter 15, 2002.
3. **Lu KH**, Bell D. Borderline Ovarian Tumors. In: Gynecologic Cancer: Controversies in Management, Elsevier Ltd, Pg 519-526, Chapter 40, 2004.
4. Ramondetta, LM, **Lu KH**. Controversies in endometrial cancer screening and diagnosis. In: Gynecologic Cancer: Controversies in Management. Pg 241-247. Elsevier Ltd, Chapter 17, 2004.
5. **Lu KH**. Prevention and Early Detection of Endometrial and Ovarian Cancers. In: Gynecologic Cancer. Chapter 2. Ed(s) PJ Eifel, DM Gershenson, JJ Kavanagh, EG Silva. Spring Scient and Business Media Inc, 12-19, 2006.
6. **Lu KH**, Broaddus R. Endometrial Cancer Associated with Defective DNA Mismatch Repair. In: Prognostic and Predictive Factors in Gynecologic Cancers. Ed(s) C Levenback, R Coleman, K Lu, A Sood. Informa UK, Ltd: London, England, 185-196, 2007.
7. Lu KH, Skates S. Hereditary Breast Cancer. In: Prognostic and Predictive Factors in Gynecologic Cancers. Ed(s) T Rebbick, C Isaccs. Informa UK Ltd: London, England, 2007.
8. **Lu KH**, Slomovitz B. Neoplastic Diseases of the Uterus. In: Comprehensive Gynecology. Chapter 32, 5th. Ed(s) VL Katz, G Lentz, R Lobo, D Gershenson. Informa UK Ltd: Longdon, England, 818-838, 2007.
9. **Lu KH**. Organ Specific Cancer Control. In: Gynecologic Cancers, ASCOs Cancer Prevention Curriculum, 2007.
10. **Lu KH**. Clinical Relevance of Hereditary Endometrial Cancer. In: Hereditary Gynecologic Cancer: Risk, Prevention, and Management. Informa Healthcare: New York City, NY, 2008.
11. **Lu KH**. Karen H. Lu, MD. In: Legends and Legacies: Personal Journeys of Women Physicians and Scientists at M.D. Anderson Cancer Center. Ed(s) EL Travis, PhD. The U T M.D. Anderson Cancer Center: Houston, TX, 107-115, 2008.
12. **Lu KH**, Keeler ER. Ovarian Cancer Screening. In: Early Diagnosis of Ovarian Cancer. Elsevier: Philadelphia, Pennsylvania, 2008.
13. Mok SC, Wong KK, **Lu K**, Munger K, Nagymanyoki Z. Molecular Basis of Gynecologic Diseases. In: Essential Concepts in Molecular Pathology. Chapter 23. Ed(s) WR Coleman and GJ Tsongalis. Academic Press: Burlington, MA, 309-322, 2010.
14. Iglesias DA, Huang M, Soliman PT, Djordjevic, **Lu KH**. Endometrial Hyperplasia and Cancer. In: Gynecologic Oncology Clinical Practice & Surgical Atlas. Chapter 6. Ed(s) BY Karlan, RE Bristow, AJ Li. McGraw Hill: China, 105-138, 2012. PMID: 978-0-07-174926-8.
15. Soliman PT and **Lu KH**. Neoplastic Diseases of the Uterus. In: Comprehensive Gynecology, 6th. Ed(s) Gretchen M. Lentz, MD, Roger A. Lobo, MD, David M. Gershenson, MD, Vern L. Katz, MD. Elsevier Mosby: Philadelphia, PA, 713-730, 2012.
16. **Lu KH**, Berchuck A, Kauff ND. Hereditary Gynecologic Cancers. In: Principles and Practice of Gynecologic Oncology. Chapter 3, 6th. Ed(s) RR Barakat, A Berchuck, M Markman, ME Randall. Lippincott Williams & Wilkins: Maryland, 60-71, 2013.

17. **Lu KH**, Klopp AH, Soliman PT. Increased Adiposity and Endometrial Cancer Risk. In: Adipose Tissue and Cancer. Ed(s) MG Kolonin. Springer: New York, NY, 53-70, 2013. PMID: 978-1-4614-7659-7.
18. Soliman PT and **Lu KH**. Neoplastic Diseases of the Uterus. In: Comprehensive Gynecology, 7th. Ed(s) Gretchen M. Lentz, MD, Roger A. Lobo, MD, David M. Gershenson, MD, Vern L. Katz, MD. Elsevier Mosby: Philadelphia, PA, 713-730, 2016.

#### **Books (edited and written)**

1. C Levenback, R Coleman, **K Lu**, A Sood. Prognostic and Predictive Factors in Gynecologic Cancers. Informa UK Ltd: London, England, 2007.
2. **Lu KH**. Ed(s) KH Lu. Hereditary Gynecologic Cancer: Risk, Prevention and Management. Informa NYC: New York, NY, 2008.
3. Merritt MA, Gunter MJ, Jochem C, Schlecht I, et al. Ed(s) Berger NA, Klopp AH, **Lu KH**. Focus on Gynecologic Malignancies. In: Energy Balance and Cancer. Series Ed(s) Berger, NA. 13. Springer, 2018. PMID: 9783319634838.

#### **Letters to the Editor**

1. Slomovitz BM, **Lu KH**. LTE - Commenting on "HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed?" Gynecol Onc 88:263-5, 2003.

#### **Manuals, Teaching Aids, Other Teaching Publications**

1. **Lu K**, Smith JA. Chemotherapy Regimens for Gynecologic Malignancies, 2003.
2. **Lu K**, Smith JA. Chemotherapy Regimens for Gynecologic Malignancies, 2004.
3. **Lu K**. Ovarian Cancer Educational CD-ROM Series. TLM Japan, 2005.
4. **Lu K**. Understanding endometrial cancer: A woman's guide. Gynecologic Cancer Foundation, 2006.
5. **Lu KH**, Mutch DG. Clinical Implications of Genetic Testing for Cancer Susceptibility. 35. Ed(s) Sokol RJ, Stone ML. The American College of Obstetricians and Gynecologists: Port Washington, NY, 1-9, 2/2010.

### **EDITORIAL AND REVIEW ACTIVITIES**

#### **Editor/Service on Editorial Board(s)**

2005 – 2013 Editorial Board, NIH, PDQ Cancer Genetics  
 2006 – 2010 Editorial Board, OBG Management  
 2007 – 2010 Editorial Board, International Journal of Gynecological Cancer  
 2007 – 2010 Editorial Board, Journal of Clinical Oncology  
 2007 – 2024 Editorial Board, Familial Cancer  
 2010 – 2019 Senior Editor, International Journal of Gynecologic Cancer  
 2016 – 2024 Editorial Board, Cancer Prevention Research

#### **Member of Editorial Review Board**

2011 – 2024 Editorial Board, Cancer Prevention Research

#### **Journal Reviewer**

2000 – 2024 Reviewer, Cancer  
 2000 – 2024 Reviewer, Clinical Cancer Research  
 2000 – 2024 Reviewer, Gynecologic Oncology  
 2000 – 2024 Reviewer, International Journal of Gynecologic Cancer  
 2000 – 2024 Reviewer, Journal of Clinical Oncology  
 2003 - 2024 Reviewer, Cancer Research  
 2004 – 2024 Reviewer, The Journal of Clinical Endocrinology & Metabolism

## **Conferences and Symposia**

### **Organization of Conferences/Symposia (Include chairing session)**

- 9/2002 1st Annual Uterine Cancer Biology Symposium, Chair
- 9/2002 3rd Annual International Conference on Ovarian Cancer, Planning Committee
- 6/2003 The University of Texas MD Anderson Cancer Center  
Chair, Early Detection of Women's Cancers - Learning Through Case  
Presentations
- 9/2004 Chair, 2nd Annual Uterine Cancer Biology Symposium
- 3/2005 36th Annual Society of Gynecologic Oncologists, Scientific Program Committee
- 10/2005 Chair, The University of Texas MD Anderson Cancer Center  
Early Detection of Women's Cancers-Partnering with the Women's Health  
Community  
Houston, TX
- 5/2006 Co-Chair, 3rd Annual Uterine Cancer Biology Symposium at  
Washington University  
St. Louis, MO
- 9/2006 Chair, GCF Endometrial Cancer Survivors Course  
UT MD Anderson Cancer Center  
Houston, TX
- 1/2007 Chair, 4th Annual Uterine Cancer Biology Symposium  
Consensus Conference on Endometrial Cancer and Lynch Syndrome:  
Identification and Management Strategies  
The University of Texas MD Anderson Cancer Center  
Houston, TX
- 5/2007 Lecturer, 2nd Annual Joining FORCES against Hereditary Cancer Conference:  
Ovarian Cancer Risk Management  
Tampa, FL
- 7/2007 Chair and Speaker, The Gynecologic Oncology Group 75th Semi-Annual  
Meeting, "Translational Research Capacities of the Gynecologic Cancer SPOREs"  
Philadelphia, PA
- 2008 Planning Committee, NIH, 2008 SPORE Workshop  
Washington, DC
- 10/2008 Co-Chair, 5th Annual Uterine Cancer Biology Symposium: Endometrial Cancer  
Biomarkers-Integrating Laboratory Discoveries into Clinical Trials  
MD Anderson Cancer Center and Memorial Sloan-Kettering  
New York, NY
- 12/2009 Chair, 6th Annual Uterine Cancer Biology Symposium  
MD Anderson Cancer Center  
Houston, TX
- 9/2010 Chair, GCF Endometrial Cancer Survivors Course, Houston, TX
- 5/2011 Chair, 7th Annual Uterine Cancer Biology Symposium: Translating Endometrial  
Cancer Research to Advance Prevention and Treatment, The University of Texas  
MD Anderson Cancer Center  
Houston, TX
- 2/2012 Organizing Committee  
Molecular Approaches to Managing Women's Cancers

- Baylor College of Medicine/MD Anderson Cancer Center Joint Symposium  
Houston, TX
- 4/2012 Chair, MD Anderson, Clinical Cancer Genetics  
Hereditary Breast and Ovarian Cancer Patient Education Conference  
Houston, TX
- 11/2013 Keynote Speaker, 2nd Annual Innovations in Oncology Symposium:  
Advances in Endometrial Cancer  
Banner MD Anderson Cancer Center  
Phoenix, AZ
- 3/2014 PARK Inhibitors Mini-Symposium Teleconference  
GYN SPORE Directors  
Boston, MA
- 4/2015 Organizing Committee, 45th Annual Meeting of the Felix Rutledge Society  
Houston, TX
- 7/2015 Co-Chair, SGO-Genetics Delivery Care Summit  
Rosemont, IL
- 4/2018 Organizing Committee, Clinical Cancer Genetics: Hereditary Cancer Symposium  
for Health Care Providers  
The University of Texas MD Anderson Cancer Center  
Houston, TX

### **Presentations at National or International Conferences**

#### **Invited**

- 1/2001 Lecturer, A Consortium to study endometrial cancer in women with HNPCC,  
Translational Working Group, Cancer Genetics Network  
Irvine, CA
- 1/2001 Lecturer, A Consortium to study endometrial cancer in women with HNPCC,  
International Collaborative Group, Hereditary Non-polyposis Colorectal Cancer  
Venice
- 3/2002 Discussant, Pathologic findings at Prophylactic Oophorectomy in high-risk  
women  
Society of Gynecologic Oncologist  
Miami Beach, FL
- 3/2002 Lecturer, Ovarian Cancer Prevention and Screening  
National Ovarian Cancer Coalition (NOCC)  
Miami Beach, FL
- 4/2002 Lecturer, National Cancer Institute Endometrial Cancer Biology Workshop  
San Francisco, CA
- 9/26/2002 Session IV Moderator: 3rd Annual International Conference on Ovarian Cancer  
Houston, TX
- 9/3/2003 Lecturer, Clinical Cases in HNPCC  
4th Joint Meeting-Leeds Castle Polyposis Group and International Collaborator  
Group Hereditary Non-Polyposis Colorectal Cancer  
Cleveland, OH
- 9/19/2003 AAOGF Endowment Scholar Lecturer  
American Gynecological and Obstetrical Society Meeting

2/2004 Napa, CA  
 Discussant, Molecular Genetic Characterization of Tamoxifen-Associated  
 Endometrial Cancer  
 Society of Gynecologic Oncologist  
 San Diego, CA

7/21/2004 Lecturer, 18th Annual Therapeutic Options for Menopausal Health Conference  
 Montreal, Canada

9/2004 Lecturer and Moderator, 2nd Annual Uterine Cancer Symposium

10/6/2004 Lecturer, High-Risk Cohorts for Endometrial Cancer  
 The 10th International Gynaecologic Cancer Society Meeting  
 Edinburgh

10/10/2004 Lecturer, ACS Clinical Congress  
 New Orleans, LA

3/2005 Course Director: Postgraduate course, "Novel technologies in molecular biology  
 for the prevention of gyn cancers,"  
 Society of Gynecologic Oncologists 36th Annual Meeting  
 Miami, FL

3/2005 Course Director: Postgraduate course, "Hereditary Gyn Cancers: Who to test and  
 how to manage,"  
 Society of Gynecologic Oncologists 36th Annual Meeting  
 Miami, FL

4/14/2005 Lecturer, Lynne Cohen Consortium Meeting - NYU  
 New York City, NY

5/8/2005 Lecturer, "Hereditary Gynecologic Cancers: Who to Test and How to Manage,"  
 Myriad CME Symposium  
 San Francisco, CA

10/19/2005 Lecturer, New England Obstetrical and Gynecological Society  
 77th Annual Fall Meeting  
 Sturbridge, MA

3/2006 Course Director, "Hereditary Gyn Cancers: Who to test and how to manage?"  
 Postgraduate course at the Society of Gynecologic Oncologists 37th Annual  
 Meeting  
 Palm Springs, CA

5/8/2006 Lecturer, "Who to Test and How to Manage," Managing Patients with Hereditary  
 Cancer Syndromes at Myriad Symposium  
 Washington, DC

9/8/2007 Lecturer, Surgical Prophylaxis for Mutation Carriers in Hereditary Cancer  
 Syndromes: Who, What, and When?  
 92nd Annual Clinical Congress of the American College of Surgeons  
 Chicago, IL

9/29/2007 Lecturer, The 2nd Biennial Scientific Meeting of International Society for  
 Gastrointestinal Hereditary Tumors, InSiGHT, Preliminary Analysis of a  
 Prospective, Multi-Center Endometrial Cancer Chemoprevention Study in  
 Women with Lynch Syndrome  
 Yokohama City, Japan

- 10/22/2007 Lecturer, Gynecologic Cancers: Summary of MD Anderson HNPCC Consortium, 11th Annual Meeting of the Collaborative Group of the Americas on Inherited Colorectal Cancer  
La Jolla, CA
- 5/6/2008 Lecturer, Screening and Early Detection of Ovarian Cancer  
ACOG 56th Annual Clinical Meeting, ACOG  
New Orleans, LA
- 9/20/2008 Management of Hereditary Ovarian Cancer and Endometrial Cancer  
17th Annual Conference of Japanese Association for Gynecologic Cancer  
Detection  
Tokyo, Japan
- 11/20/2008 Integration of Hereditary Cancer Genetics into Clinical Oncology  
The Norwegian Oncology Meeting  
Bergen, Norway
- 5/2/2009 Lecturer, The John and Marney Mathers Lecture: "Reproductive and Psychosocial Issues in Women with the BRCA Mutation,"  
ACOG 57th Annual Clinical Meeting  
Chicago, IL
- 9/10/2009 Panelist: "Clinical Implications of Genetic Testing for Cancer Susceptibility,"  
AGOS 2009 Annual Meeting  
American College of Obstetricians and Gynecologists  
Chicago, IL
- 11/7/2009 Moderator: Endometrial Cancer Survivors Course  
Gynecologic Cancer Foundation  
Washington, DC
- 12/2/2009 Lecturer, "From the Bench to Clinical Practices: A Focus on Endometrial Cancer,"  
SGO 40th Annual Meeting on Women's Cancer  
San Antonio, TX
- 2/18/2010 Lecturer, "Updates in Ovarian Cancer Screening and Familial Cancer Syndromes," II  
MD Anderson International Conference in Gynecologic Oncology  
Madrid, Spain
- 3/14/2010 Lecturer, "A Prospective, Multi-center Randomized Study of Oral Contraceptive,"  
SGO Annual Meeting on Women's Cancer  
San Francisco, CA
- 10/13/2010 Lecturer: "Lynch Syndrome and Gynecologic Operations: Proactive or Reactive?"  
14th Annual Meeting Collaborative Group of the Americas on Inherited Colorectal Cancer (CGA-ICC)  
Dallas, TX
- 10/31/2010 Lecturer: Plenary Session I: Hereditary Gynecologic Cancer  
13th Biennial Meeting of the International Gynecologic Cancer Society  
Prague, Czech Republic
- 2010 Lecturer: "Less is More: The Emerging Role of Molecular Analysis,"  
ASTRO'S 52nd Annual Meeting  
San Diego, CA,
- 12/4/2010 Lecturer-"Screening the Low-risk Patient for Ovarian Cancer,"

SGO-State of the Art Conference  
Chicago, IL

1/27/2011 Lecturer, "Review of Current Translational Research and SPORE Projects in Endometrial Cancer,"  
Gynecologic Oncology Group 82nd Semi-Annual Meeting  
San Diego, CA

3/4/2011 Course Director - "Express Postgraduate 1: Hereditary Gynecologic Malignancies: Clinical Management and Developing Controversies,"  
SGO 42nd Annual Meeting on Women's Cancer  
Orlando, FL

3/6/2011 Discussant: "Management of complex pelvic masses using the OVA1 test: A decision analysis,"  
SGO 42nd Annual Meeting on Women's Cancer  
Orlando, FL

3/6/2011 Discussant: "Predictors and Effects of Reduced Relative Dose Intensity in Women Receiving Primary Course of Chemotherapy for Ovarian Cancer,"  
SGO 42nd Annual Meeting on Women's Cancer  
Orlando, FL

3/7/2011 Lecturer: "A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA)" & Panel Discussion with Q&A  
SGO 42nd Annual Meeting on Women's Cancer  
Orlando, FL

4/2/2011 Lecturer: "Gynecology Surveillance Strategies,"  
4th Biennial InSiGHT Meeting  
San Antonio, TX

6/3/2011 Endometrial Cancer: Present State and Future Promise  
"Molecular Characterization of Endometrial Cancer: Going Beyond Histology,"  
ASCO Annual Meeting, Chicago, IL, 6/3/2011  
Lecturer: "Screening After Surgery,"  
6th Annual Joining Forces Against Hereditary Cancer (FORCE), Orlando, FL

6/25/2011 Session V: Ovarian Cancer Risk-Management Panel  
6th Annual Joining Forces Against Hereditary Cancer (FORCE)  
Orlando, FL

9/23/2011 Cancer in Women, The Center for Asian Pacific American Women  
2011 National Leadership Summit  
Houston, TX

10/14/2011 Genetics and Cancer Survivors  
Cancer Survivorship Conference for Physicians and Other Healthcare Professionals  
The University of Texas MD Anderson Cancer Center  
Houston, TX

10/23/2011 Chairperson: Prevention of Gynecologic Cancers: Ovary, Uterus, and Cervix  
AACR 10th Annual Frontiers in Cancer Prevention Research  
Boston, MA

- 10/24/2011 Lecturer: "Endometrial Cancer: High Risk Cohorts and Strategies for Prevention,"  
Tenth Annual AACR International Conference on Frontiers in Cancer Prevention  
Research  
Boston, MA
- 12/2/2011 Lecturer: Screening for Ovarian Cancer in the General Population  
9th International Conference on Ovarian Cancer  
MD Anderson Cancer Center  
Houston, TX
- 9/28/2012 Keynotes Address: Lynch syndrome: The Gynecologic Oncologist's Experience,  
US Oncology-Topics in Cancer Genetics: A Review and Update for the  
Community Oncologist  
Meniscus Education Institute  
Las Vegas, NV
- 10/15/2012 Chairperson: Should All Ovarian Cancer Patients Undergo BRCA Mutation  
Testing?  
IGCS Biennial Meeting  
Vancouver, Canada
- 12/1/2012 Lecturer, "Review of Main Translational Research and Targeted Therapy Issues,"  
GCIG Endometrial Cancer Clinical Trials Planning Meeting  
Gynecologic Cancer Intergroup/Leiden University Medical Center  
Leiden, Netherlands
- 3/9/2013 Moderator, "Controversies in Ovarian Screening," Education Forum III:  
Gynecologic Cancer Genetics: The Practical Implications, Society of  
Gynecologic Oncology 44th Annual Meeting on Women's Cancer  
Los Angeles, CA
- 3/23/2013 Lecturer: "Controversies in Ovarian Cancer Screening,"  
Women's Health 2013: The 21st Annual Congress  
Washington, DC
- 4/4/2013 Lecturer, "Hereditary Gynecologic Cancers,"  
The Bruce A. Harris Symposium Progress in Ob/Gyn 2013 Meeting  
University of Birmingham School of Medicine  
Birmingham, AL
- 10/23/2013 Lecturer, "Ovarian Cancer: Developing Research-Based Public Messaging on  
Early Detection and Screening,"  
Ovarian Cancer Research Fund  
Banbury Center, Cold Spring Harbor Laboratory  
Cold Spring Harbor, NY
- 2/19/2014 Opening Key Lecturer: "Gynecologic Cancer Genetics:  
The Practical Implications,"  
MD Anderson International Meeting in GYN ONC  
"Emerging Therapies in Gynecologic Cancer"  
Madrid, Spain
- 5/15/2014 Lecturer: "Uterine Specialized Programs of Research Excellence:  
Update," Felix Rutledge Society Annual Meeting  
Scottsdale, AZ

6/2/2014 Discussant: "Emerging Strategies for Gynecologic Cancer Risk Assessment,"  
ASCO 2014 Annual Meeting  
Chicago, IL

9/11/2014 Lecturer: "Prevention of Endometrial Cancer in Obese Women,"  
AGOS 2014 Annual Meeting  
Chicago, IL

4/19/2015 Lecturer, Recent Advances in Epidemiology and Prevention Research;  
"Epidemiology of Obesity and Endometrial Cancer,"  
AACR  
Philadelphia, PA

4/30/2015 Lecturer: "Update on BRCA Testing and the Women's Cancer Moonshot,"  
Felix Rutledge Society Annual Meeting, Houston, TX

5/1/2015 Panelist: "Leadership in the Academic Arena,"  
Felix Rutledge Society Annual Meeting  
Houston, TX

5/31/2015 Lecturer, Epidemiology: From Genetics to Practice:  
"Value of Family History in Common Cancers,"  
ASCO, Chicago, IL

11/7/2015 Discussant: "What defines the clinical subgroups that should be used for  
comparator trials?"  
Ovarian Cancer Consensus Conference  
Tokyo, Narita, Japan

2/24/2016 Keynote Lecturer: "Hereditary Cancer Genetics in the Era of Targeted Therapies,"  
MD Anderson International Meeting in GYN Onc:  
"Tailoring Cancer - Therapy in the Era of Personalized Medicine"  
Madrid, Spain

3/5/2016 Discussant: "Promises and Challenges Associated with Next Generation  
Sequencing,"  
CROEG & APGO Annual Meeting:  
"The Big & Not So Easy: Today's Challenges in Medical Education"  
New Orleans, LA

10/17/2016 Speaker "Genetics of Ovarian Cancer,"  
Italian Society of Gynecology and Obstetrics (SIGO)  
Rome, Italy

10/29/2016 Plenary Session: Clinical and Genetic Screening for Epithelial Ovarian Cancer:  
Future of Screening for Germline & Somatic Mutations  
IGCS Semi-Annual Conference  
Lisbon, Portugal

3/25/2018 Lecturer, Advances in the Evaluation and Management of Lynch Syndrome  
Society of Gynecologic Oncology  
New Orleans, LA

3/17/2019 Lecturer, WISP: A prospective, multi-center trial of salpingectomy with delayed  
oophorectomy versus risk reducing salpingo-oophorectomy in women at  
increased risk for hereditary ovarian cancer  
SGO 50th Annual Meeting on Women's Cancer  
Honolulu, HI

- 5/17/2019 Lecturer, Lessons Learned from my time as CMO  
Felix Rutledge Society Annual Meeting  
Houston, TX
- 9/13/2019 Presenter: Women at high-risk for ovarian cancer:  
Novel strategies for identification and prevention  
Advances in Ovarian Cancer Research  
AACR  
Atlanta, GA
- 11/5/2019 Talk with Case Example: Pros and Cons and the Timing of Prophylactic TAH in  
LS, Collaborative Group of the Americas Annual Meeting  
Salt Lake City, UT
- 1/30/2021 Lecturer: 9th Annual Arts of Healing Gyn Cancer Survivor VIRTUAL  
Conference: Cutting Edge Ovarian Cancer Prevention and Early Detection  
Strategies, Let Every Woman Know — Alaska, Virtual, TX
- 7/13/2021 Panelist: The Art of Saying No  
SITC WIN Leadership Institute, Virtual, TX

#### **Other, Including Scientific Exhibitions**

- 3/5/2016 Lecturer: "Promises and Challenges Associated with Next Generation  
Sequencing," Lecturer: "The Big & Not So Easy: Today's Challenges in Medical  
Education," CREOG & APGO Annual Meeting  
New Orleans, LA
- 4/8/2016 Keynote Speaker: "Risk Reducing Strategies for Gynecologic Malignancies,"  
"New Frontiers in Diagnosis, Screening and Management of Inherited Cancer  
Syndromes" at University of Chicago  
Chicago, IL
- 5/13/2016 Speaker: "Update on MD Anderson Research Collaborations,"  
46th Annual Meeting of the Felix Rutledge Society  
Nashville, TN
- 11/11/2021 Speaker, Salpingectomy for ovarian cancer risk reduction in high-risk women,  
Ovarian Cancer Midwest Focus (OCMF) Conference 2021, Virtual, TX

#### **Seminar Invitations from Other Institutions**

- 3/21/2019 Environmental risk factors and tumor genomic profiles: a clinical perspective,  
Radcliffe Institute for Advanced Study  
Cambridge, MD
- 4/25/2019 Understanding the Interface Between Benign and Malignant:  
Impact on Cancer Prevention, NCI, NCI-NICHD  
Rockville, MD
- 9/1/2020 The MAGENTA Study: A New Genetic Testing Paradigm for Increased  
Accessibility Webinar  
NCI ENRICH Forum  
Houston, TX

#### **Lectureships and Visiting Professorships**

- 10/9/2002 Lecturer, Update on Hereditary Gynecologic Cancers

Baylor/Methodist OB/GYN Grand Rounds  
Houston, TX

5/11/2005 Lecturer, The 7th Scientific Session - The John I. Brewer Memorial Lecture entitled "Update in Ovarian Cancer Screening and Prevention," Annual Clinical Meeting of the American College of Obstetricians and Gynecologists  
San Francisco, CA

5/10/2006 Lecturer, 8th Scientific Session - The John and Marney Mathers Lecture entitled "Hereditary GYN Cancers: Genetic Testing and the Role of the Obstetrician Gynecologist," Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, Washington, DC

11/1/2007 Lecturer, "Hereditary Gyn Cancers," 78th Annual Joint Meeting of ACOG Texas Section and The Texas Association of Obstetricians and Gynecologists  
Houston, TX

11/1/2007 Visiting Professor, The Gail Klein Garlove Lectureship "The Era of Personalized Medicine: Identification and Management of Individuals at Increased Risk for Cancer," Norton Hospital, Louisville, KY

1/4/2008 Lecturer, "Familial Endometrial Cancer," Institutional Grand Rounds  
The Woman's Hospital of Texas, Houston, TX

3/10/2010 Visiting Professor, "Endometrial Cancer: Insights into Pathogenesis and Prevention," University of British Columbia  
Vancouver, Canada

12/2/2010 Visiting Professor, "Endometrial Cancer: Insights into Pathogenesis and Prevention," Donald Jones, MD Lecture  
Ohio State University, Columbus, OH

2/10/2011 Visiting Professor, "Endometrial Cancer: High Risk Cohorts and Prevention," PCPR Seminar, Memorial Sloan Kettering, New York, NY

2/10/2011 Visiting Professor, "Lynch Syndrome: Defining Clinical Relevance," Gynecologic Disease Management Conference  
Memorial Sloan Kettering, New York, NY

7/21/2011 Visiting Professor, "Endometrial Cancer: Insights into Pathogenesis and Prevention," Grand Rounds, Stanford University, Obstetrics and Gynecology, Stanford, CA,  
7/21/2011

9/19/2011 Visiting Professor, "Update on Ovarian Cancer," Women's Cancer Symposium, Carol G. Simon Cancer Center at Morristown and Overlook Medical Centers,  
Morristown, NJ

1/30/2012 Visiting Professor, "Ovarian Cancer Update," 2012 Time is of the Essence Luncheon, HOW (Hearing the Ovarian Cancer Whisper)  
West Palm Beach, FL

3/21/2012 Visiting Professor, "Endometrial Cancer: Insights into Pathogenesis and Prevention,"  
Washington University, Department of OB & GYN  
St. Louis, MO

4/13/2013 Visiting Professor, "Endometrial Cancer: Advances in Prevention and Treatment,"  
Yale University, New Haven, CT

4/3/2013 Visiting Professor, "Incorporating Cancer Genetics into the Practice of Obstetrics and Gynecology," Cancer Center Talk  
University of Alabama Women's and Infant Center, Obstetrics and Gynecology  
Birmingham, AL

6/8/2013 Visiting Professor, "Hereditary Gynecologic Cancers,"  
Harvard University, Dept of Obstetrics and Gynecology  
Boston, MA

9/6/2013 Visiting Professor: "Developing A Uterine Cancer Translational Research Program,"  
Peggy and Charles Stephenson Cancer Center at The University of Oklahoma,  
The University of Oklahoma, Gynecologic Oncology  
Oklahoma City, OK

9/20/2013 Visiting Professor: "Update on Ovarian Cancer Screening and Prevention,"  
Dr. Arthur Herbst Lecture in Gynecologic Oncology  
University of Chicago, Dept of Obstetrics and Gynecology  
Chicago, IL

12/11/2013 Visiting Professor, "Management of BRCA Mutation Carriers: Update for OB GYNs,"  
LSU Grand Rounds, LSU School of Medicine - New Orleans  
LSU Health Sciences Center, New Orleans, LA

3/26/2014 Visiting Professor: "Progress in Ovarian Cancer Screening and Prevention,"  
Joan W. Gibson Lectureship in Women's Oncology  
University of Virginia, Gynecologic Oncology  
Charlottesville, VA

6/5/2014 Visiting Professor: "Progress in Ovarian Cancer Screening and Prevention,"  
MGH Vincent OB/GYN Grand Rounds  
Massachusetts General Hospital, OB/GYN, Boston, MA

5/6/2015 Visiting Professor: "Genetics of GYN Cancers,"  
Women's Health Services Grand Rounds  
Henry Ford Health System, Detroit, MI

5/13/2015 Visiting Professor; "Progress in Ovarian Cancer Screening and Prevention,"  
University of Colorado School of Medicine, Denver, CO

9/10/2015 Visiting Professor; "Progress in Ovarian Cancer Screening and Prevention,"  
TeLinde Lecture, John Hopkins, Baltimore, MD

10/15/2015 Visiting Professor; "Using Genomics to Develop New Therapies for the Conservative Management of Endometrial Cancer,"  
2015 Memorial Hospital Alumni Society Conference  
Memorial Sloan Kettering Cancer Center, New York, NY

10/28/2015 Visiting Professor: "New Strategies for Ovarian Cancer Prevention in High-Risk Women," Monthly Genetics Lecture Series

- 11/19/2015 Dana-Farber Cancer Institute, Gynecology, Boston, MA  
Visiting Professor: "New Strategies for Ovarian Cancer Prevention in High-Risk Women," GYN Cancer Interest Group Seminar  
Mayo Clinic, Gynecology, Rochester, MN
- 4/7/2016 Visiting Professor: "Update in Early Detection and Prevention of Ovarian Cancer," "Work in Progress" Meeting at Magee Women's Research Institute, Pittsburgh, PA
- 9/12/2016 Visiting Professor: "Impacting Ovarian Cancer Mortality Through Prevention Strategies," 11th Biennial Ovarian Cancer Research Symposium  
University of Washington, Seattle, WA
- 1/14/2022 Lecture, New Paradigms for Genetic Testing and Ovarian Cancer Prevention, Carillion Clinic Ob/Gyn Grand Rounds, Virtual

### **Other Presentations at State and Local Conferences**

- 4/2002 Visiting Speaker: Course on Obesity  
UT School of Public Health  
Houston, TX
- 10/26/2002 Invited Speaker: Hereditary Cancer Screening and Testing for the Primary Care Physician, Primary Care Summit  
Texas Academy of Family Physicians  
Houston, TX
- 10/29/2002 Invited Speaker: Women's Health, Are You in the Know?  
Executive Women's Partnership Forum  
Greater Houston Partnership  
Houston, TX
- 3/3/2003 Invited Speaker: "Hereditary Gynecologic Cancers: Are you at risk?"  
Bryan-College Station Business and Professional Women  
Bryan, TX
- 4/24/2003 Visiting Speaker: Course "Molecular and Genetic Basis of Obesity"  
"Obesity, cancer and women,"  
UT School of Public Health  
Houston, TX
- 4/24/2003 Invited speaker: Beyond the Pap Smear  
The Healthy Woman's Symposium and Luncheon 2003  
Houston, TX
- 4/27/2003 Invited speaker, Free Education Program on Ovarian and Breast Cancer:  
Screening for Women at Increased Risk of Ovarian Cancer  
Jewish Community Center  
JoAnn Rosenberg Fund for Ovarian Cancer Education  
Houston, TX
- 9/2003 Visiting Speaker: Trophoblastic Diseases, Grand Rounds  
Memorial Hermann Southwest  
Houston, TX
- 10/14/2003 Invited speaker: "Does your family history put you at risk for women's cancer?"  
"Julie Rogers Gift of Life Program"  
5th Annual Women's Health Forum

- Lamar University  
Beaumont, TX
- 1/27/2004 Invited speaker: "Hereditary Gynecologic Cancers in your Practice,"  
Myriad Genetics  
Houston, TX
- 3/27/2004 Invited speaker: "Does Your Family History Put You At Risk For Cancer?"  
Leadership Texas Conference
- 4/2004 Visiting Speaker: Course "Molecular and Genetic Basis of Obesity"  
"Obesity, cancer and women,"  
UT School of Public Health  
Houston, TX
- 5/7/2004 Invited speaker: "Clinico-Pathologic and Molecular Analysis of Endometrial  
Cancers in Women with HNPCC,"  
Business Professional Women of Texas & UTMDACC Annual Award Ceremony  
Houston, TX
- 5/21/2005 Invited Speaker: "Journey to Wellness: Destination Health"  
"10 Questions to Ask Your Gynecologist,"  
University of Texas MD Anderson Cancer Center  
Houston, TX
- 10/23/2005 Invited Speaker: Screening for Women at Increased Risk of Ovarian Cancer  
Free Education Program on Ovarian and Breast Cancer  
Jo Ann Rosenberg Fund for Ovarian Cancer Education and Hadassah Group  
Sugarland, TX
- 4/1/2007 Invited Speaker: Hereditary Breast and Ovarian Cancer: Information for You and  
Your Family  
The Beth Sanders Moore Young Breast Cancer Survivors' Program Spring  
Workshop, Houston, TX
- 6/1/2007 Invited Speaker: Update in Endometrial Cancer  
The 37th Annual Meeting  
The Felix Rutledge Society  
Houston, TX
- 6/1/2008 Invited Speaker: Gynecologic Cancer, Breast and Gynecologic Cancer Workshop:  
Basics, Genetics, Prevention and Screening, Light and Salt Association-Breast  
Cancer Support Group  
American Cancer Society-Asian Cancer Counsel  
Houston, TX
- 2/2/2012 Panel Discussion with Senior Women Faculty, Build Your Career to Success:  
A workshop for early career women faculty at MD Anderson Cancer Center  
MD Anderson Cancer Center-Women Faculty Programs  
Houston, TX
- 2/3/2012 Invited Speaker: Targeted Therapy for Endometrial Cancer, Molecular Approaches  
to Managing Women's Cancers  
Baylor College of Medicine/MD Anderson Cancer Center Joint Symposium  
Houston, TX
- 2/3/2012 Session Chair: Prevention, Early Detection and Diagnostic Biomarkers, Molecular  
Approaches to Managing Women's Cancers

Baylor College of Medicine/MD Anderson Cancer Center Joint Symposium  
Houston, TX

4/4/2012 Invited Speaker: HBOC Ovarian Cancer Management, Hereditary Breast and  
Ovarian Cancer Patient Education Conference  
MD Anderson Cancer Center, Clinical Cancer Genetics  
Houston, TX

3/20/2013 "Making Cancer History for the Family,"  
2013 VEPS Luncheon, Volunteer Endowment for Patient Support  
MD Anderson Cancer Center, Volunteer Services  
Houston, TX

5/23/2013 "Optimizing the Identification of Hereditary Gynecologic Cancers,"  
Clinical Cancer Genetics Grand Rounds  
Department of Gynecologic Oncology and Reproductive Medicine  
University of Texas M.D. Anderson Cancer Center, Houston, TX

8/7/2013 Moderator. "Personalizing Surgical Therapy for Ovarian and Uterine Cancer,"  
Division of Surgery Grand Rounds  
University of Texas MD Anderson Cancer Center  
Department of Gynecologic Oncology and Reproductive Medicine  
Houston, TX

9/22/2013 "Ovarian Cancer Genetics,"  
Ovarian Cancer Regional Seminar  
Ovarian Cancer National Alliance and MD Anderson Cancer Center,  
MD Anderson Cancer Center  
Houston, TX

10/5/2013 "Incidental Germline Variants: Clinical Perspectives,"  
Symposia on Cancer Research 2013: Genomic Medicine  
University of Texas MD Anderson Cancer Center  
Houston, TX

11/14/2013 Lecturer, "Benefit of Exercise and Healthy Eating in the Treatment of Cancer and  
Ovarian Cancer Test for Detection,"  
Cedar Hill "Inspiring Women's Health,"  
The Chamber of Cedar Hill  
Cedar Hill, TX

12/10/2013 Lecturer, "New Developments in Ovarian Cancer Screening and Prevention,"  
OB/GYN Society of New Orleans  
New Orleans, LA

9/17/2014 Invited Speaker: "When Your Patient Asks: New Answers About Ovarian Cancer  
Prevention and Screening,"  
HGOS September General Meeting  
Houston Gynecological & Obstetrical Society (HGOS)  
Houston, TX

9/29/2014 Invited Speaker: "Prevention of Genetic and Non-Genetic Breast and Ovarian  
Cancer,"  
Ovarcome 2nd Annual Breakfast Summit: 2014  
Ovarcome, Houston, TX

10/3/2014 Work-Life Integration, "Lunch and Learn"

Session at Women's Faculty Programs MD Anderson Cancer Center  
 Houston, TX

3/31/2016 Invited Speaker: "Latest Advances in Women's Cancers,"  
 Ovarcome Annual Luncheon, Ovarcome  
 Houston, TX

10/8/2016 Invited Panelist: Women Surgeons - Learn their strategies and tactics for  
 navigating the complicated dynamics of an operating room  
 Women and Minority Faculty Inclusion  
 Faculty Women and Minority Affairs and Academic Development  
 MD Anderson Cancer Center  
 Houston, TX

2/3/2017 Invited Panelist: "The Hot Commodity: Managing Work-Life Integration,"  
 Developing Your Leadership Potential: Pathways to Leadership for Women  
 Assistant and Associate Professors  
 Faculty Women & Minority Affairs and Academic Department  
 University of Texas MD Anderson Cancer Center  
 Houston, TX

4/9/2019 Advances in Clinical Cancer Genetics  
 Dallas Making Cancer History® Seminar  
 The University of Texas MD Anderson Cancer Center  
 Development Office - Special Programs  
 Dallas, TX

9/27/2019 Invited Speaker: GENEOLGY: Ovarian Cancer Genetics, Latest Advances in  
 Prevention & Treatment, Ovarcome Annual Conference, Ovarcome  
 Houston, TX

10/11/2019 Teaming with Employers for Cancer Care Excellence  
 MD Anderson Cancer Network Member Meeting  
 The University of Texas MD Anderson Cancer Center  
 Cancer Network, Houston, TX

5/20/2021 MD Anderson's 1st Asian American and Pacific Islander Heritage Month  
 Celebration Panelist for the virtual discussion: Addressing the Needs of the Asian  
 American and Pacific Islander (AAPI) Community  
 The University of Texas MD Anderson Cancer Center,  
 Houston, TX

6/8/2021 Making Cancer History® Virtual Seminar Series  
 Emcee, The University of Texas MD Anderson Cancer Center  
 Houston, TX

10/13/2022 Lu K. Pathology and Genetics of Lynch Syndrome  
 UPR/MDACC Advanced Topics in Cancer Research: Personalized Cancer  
 Medicine course  
 Houston, TX

10/13/2022 MDA Making Cancer History Virtual Seminar Series IV  
 What' New: Women's Cancer Research in Review, EMCEE

10/25/2022 Early detection of ovarian cancer  
 Tina's Wish

11/3/2022 The 40th National & 9th International Oncology Meeting of the Mexican Society of Oncology (SMeO): From timely detection to genetics in ovarian cancer - Ovarian cancer risk reduction surgeries and actual trends  
Mexican Society of Oncology

11/8/2022 Greater Than One Workshop with the entire Opportunistic Salpingectomy team  
Opportunistic Salpingectomy Team

10/13/2023 OncLive National Fellows Forum  
OncLive

7/18/2024 Keynote Speaker, Stovall House, Tampa, FL

2/28/2025 Grand Rounds, Women in Oncology; Crafting Your Leadership Journey: Planning for Successes, Learning From Failures, Moffitt Cancer Center, Tampa, FL

4/10/2025 Grand Rounds, Implementing Salpingectomy as a Prevention Option for High-risk Women, University of Miami, Miami, FL